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ABSTRACT
This thesis describes the structure determination of the MyoD
basic-helix-loop-helix (bHLH) region bound specifically to its DNA
site, and discusses the implications of the structure for
understanding recognition and regulation.
Chapter provides an introduction to the biology of the
myogenic proteins, of which MyoD is a member. Many f the
important biological activities of the myogenic proteins, including
DNA binding, dimerization, and control of transcription, are
mediated through the bHLH regions of these proteins.
Chapter 2 describes the cocrystallization experiments with
MyoD peptides containing the bHLH region and a series of synthetic
DNA oligonucleotides. The purity of the MyoD peptide and the
sequence and length of the synthetic DNA oligonucleotide used for
the cocrystallization were crucial for obtaining crystals suitable
for structure determination.
Chapter 3 describes the determination of the structure of the
MyoD/DNA complex. We used the method of multiple isomorphous
replacement using DNA which had 5-iodouracil substituted for
thymine. Purification of the iodine-substituted DNA oigomers was
critical for obtaining isomorphous crystals suitable for phasing.
3Chapter 4 presents the structure of the MyoD/DNA complex.
We focus on structural aspects of DNA recognition, and
transcriptional activation. We find that two of the three residues,
Ala 1 4 and Thr 1 1 5, which are important for positive control, are
buried within the major groove of the DNA, and not easily
accessible for protein-protein interactions. Analysis of the
structure suggests that these two residues may affect
transcriptional activation by determining the position of a
neighboring arginine. The experiments from this chapter will be
published as "Crystal Structure of MyoD bHLH-DNA Complex:
Perspectives on DNA Recognition and Implications for
Transcriptional Activation" (Ma, P.C.M., Rould, M.A., Weintraub, H.,
and Pabo, C.O. (I 994) Cell (in press) .
Chapter expands upon aspects of the MyoD/DNA structure
which were not discussed in detail in Chapter 4 In particular we
focus on the structural determinants for dimer formation among the
bHLH proteins.
Chapter 6 summarizes the structural analysis from Chapters 4
and and suggests possible directions for future research.
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Proteins involved in gene regulation often have a modular
architecture, being composed of several domains. By studying the
function of these separate domains in addition to studying how
these domains interact with each other, we can better understand
the mechanisms of gene regulation. The transcriptional activity
originally identified as TAID, for example, now has been separated
into a TATA-binding protein (TBP), which binds DNA, and several
TATA-associated factors (TAFs), which appear to interact with and
modulate the activity of RNA polymerase 11 (Dyniacht et al., 1991;
Hoey et al., 1993; Weinzierl et al., 1993). Modularity of protein
structure and function becomes even more pronounced in the control
of gene expression beyond the basal level. The Myol) (Davis et al.,
1987) family of proteins, which also includes Myf-5 (Braun et al.,
1989b), MRF4 (Rhodes and Konieczny, 1989) and myogenin (Edmond-
son and Olsen, 1989), regulates myogenesis by controlling tissue-
and temporally-selective gene expression in myoblasts and
ffryotubes; these proteins are not present in fibroblasts or other
non-muscle cell types (Weintraub et al., 1991). The myogenic
proteins interact with each other, either directly or indirectly, and
appear to take part in an autoregulatory loop of gene expression.
Myol) can activate its own expression as well as the expression of
n'ryogenin, while myogenin and Myf-5, in turn, can activate their own
expression and that of Myol) (Braun et al., 1989a; Thayer et al.,
1989; Edmondson et al., 1992). Myol) appears to play a central role
in the early stages of myogenesis. Expression of the Myol) gene
alone is necessary and sufficient to induce myogenesis in 1 OT 12
fibroblasts (Weintraub et al., 991 ). Moreover, for this induction of
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myogenesis, only 68 amino acids of Myol) are required. This 68
amino acid region, known as the 'basic-helix-loop-helix' (bHLH)
motif (first identified by sequence analysis (Murre et al., 1989a)
shows homology to the other myogenic proteins, as well as to the
oncogenic myc-family of proteins, to proteins involved in
Drosophila sex and neuronal development, and to the E2A proteins
E47 and El 2 which bind the immunoglobulin enhancer sequence
(Murre et al., 1989b).
In addition to Mol) itself, expression of other members of the
Myol) family (Myf-5, myogenin, and MRF4) in fibroblasts and a
variety of other cell types can convert these different cell types
into muscle (Buckingham, 1992; Wright, 1992). It was thus thought
that the Myol) gene family played master regulatory roles in
skeletal muscle determination (Weintraub et al., 1991). In contrast
to the results of the cell culture experiments, which suggested a
fairly straightforward role for the Myol) family genes in muscle
development, the results of recent gene knockout experiments in
mice reveal a more complex mechanism for myogenic gene regula-
tion. Mice with homozygous knockouts of either Myf-5 or MyoD
produced close to normal amounts of muscle (Braun et al., 1992;
Rudnicki et al., 1992). The two mutant mice strains had distinct
phenotypes. For the Myf-5-negative mice, although there was
seemingly no effect on muscle development, the mice failed to
develop a normal rib cage. In fact, the rib cage development was so
impaired in the Myf-5-negative mice that the mice had severe
respiratory problems and died immediately after birth. (Braun et al.,
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1992). For the MyoD-negative mice, there was survival after birth,
but a lower viability than for the wild-type (Rudnicki et al., 1992).
The results of the single gene knockout experiments for MyoD and
Myf-5 thus seemed to conflict with the results of the cell culture
experiments with respect to the importance of the Myol) gene
family for muscle development. This apparent paradox was resolved
recently in a double knockout experiment involving both the MyoD
and Myf-5 genes. Double homozygous mutants for MyoD and Myf-5,
produced from a genetic cross of the two single homozygous
mutants, had an interesting phenotype (Rudnicki et al., 1993). They
were born alive, but were immobile and died soon after birth.
Closer examination of the mice revealed that they did not express
skeletal muscle-specific genes, did not have any skeletal muscle
formation, and did not express any markers for skeletal muscle,
revealing that myoblasts did not form in these mice. It thus
appears that MyoD and Myf-5 are at least partially redundant for the
determination of skeletal myoblasts, but that expression of at least
one of the genes is absolutely necessary for myoblast formation.
In addition to the single and double gene knockout experiments
for MyoD and Myf-5, there has also been a recent study of a gene
knockout for myogenin (Hasty et al., 1993). Like the MyoDIMyf-5
double knockout mice, the myogenih-negative mice died immedi-
ately after birth with a severe reduction of skeletal muscle.'The
mutant mice expressed normal levels of MyoD rnRNA, indicating that
myoblasts had formed, but histological analysis revealed that these
myoblasts failed to differentiate fully into myotubes. Thus, it
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appears that Myol) or Myf-5 are necessary for myoblast determi-
nation, but that myogenin is needed for proper differentiation of the
myoblasts into muscle (Weintraub, 1993).
Given the partially overlapping functions of the myogenic
proteins, as revealed by cell culture and gene knockout experiments,
it is not surprising that the Myol) gene family would share some
structural similarities as well. Sequence analysis of the Myol) gene
family reveals a particularly strong homology in the bHLH motif
among these proteins. There is an 81 % strict homology and 73%
sequence similarity among 0 of the 68 amino acids that comprise
the bHLH motif in MyoD, Myf-5 and myogenin. All of the myogenic
proteins oligornerize, bind DNA, and activate transcription. The
bHLH motif is necessary for all of these functions and sufficient for
oligornerization and DNA-binding (Weintraub et al., 1991). The
oligomerization function is of primary importance because bHLH
proteins, like the basic-leucines zipper (bZIP) proteins such as the
yeast transcription factor GCN4, only bind DNA as homo- or hetero-
dimers. The myogenic proteins appear to function best as hetero-
dimers with E47 or El 2 Myol) forms homodimers less efficiently
than it forms heterodimers with El 2 or E47 (Sun and Baltimore,
1991; Fairman et al., 1993). Once Myol) homodimers are formed,
however, they appear to bind DNA with a similar, but lower
efficiency than MyoD-E47 heterodimers (Sun and Baltimore, 991;
Blackwell and Weintraub, unpublished).
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It appears, then, that the activity of the MyoD family of pro-
teins may be positively regulated through interaction with the E-
proteins. Other experiments reveal that the MyoD family may be
subject to significant negative regulation as well. The Id (inhibitor
of DNA binding) protein contains a helix-loop-helix (HLH) motif, and
has been show to prevent DNA binding of other HLH-containing
proteins (Benezra et al., 990). Id lacks a functional basic region
and can inhibit the DNA-binding function of proteins from the MyoD
or E2 family through the formation of inactive heterodimers
(Benezra et al., 990; Sun et al., 991 ). In addition to Id, other
proteins have been shown to negatively regulate the activity of the
myogenic proteins. Many of these negative regulators are involved
with the control of the cell cycle. In the development of muscle
cells, terminal differentiation of cells is mutually exclusive to cell
proliferation (Olson et al., 991 ). Before myoblasts fuse to form
myotubes, they withdraw from the cell cycle (Miller, 992). During
this withdrawal from the cell cycle, myogenesis and the activity or
expression of the myogenic proteins is inhibited by a number of
negative regulators. The Ras and Fos oncogenes inhibit both MyoD
transcription and MyoD activity (Lassar et al., 989). Jun can
physically interact through the helix-loop-helix region of MyoD and
the leucine zipper region of Jun; this physical interaction is thought
to inhibit the activity of both genes (Bengal et al., 1992). Direct
and/or indirect interactions between Transforming growth factor-
beta (TGF-P ) and myogenin (Martin et al., 992) and between the El A
gene product and myogenin (Taylor et al., 993) have also been
demonstrated. In both cases, the interaction results in an inhibition
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of myogenin activity and is mediated through the basic-helix-loop-
helix region of the protein. It is clear then, that the activities of
MyoD and the other members of the family are extensively regulated
by interactions with other proteins. A large number of positive and
negative signals probably act directly on the Myol) family proteins
during the entire muscle development process, from determination
to final differentiation.
Protein-protein interactions have an important role in con-
trolling the activities of the myogenic proteins. Moreover, protein-
protein interactions are intimately involved in the activity of the
myogenic proteins themselves. The members of the Myol) family of
proteins bind DNA as homodirners or as heterodimers with the E-
proteins El 2 and E47 (Murre et al., 1 989b; Davis et al., 990; Lassar
et al., 1991). In addition to stabilizing the structures of the indi-
vidual proteins [the Myol) monomer is to a large extent, unstruc-
tured (Anthony-Cahill et al., 1992)], the formation of homo- and
heterodimers also helps determine the specificity of DNA binding.
All bHLH proteins recognize a consensus DNA binding site known as
the E-box (CANNTG) that is present in the regulatory regions of
many tissue-specific genes; these include the muscle specific
genes for the myosin light chain and the muscle creatine kinase
(Weintraub et al., 991). Myol) and E47 show preferential binding to
different DNA sites. (Blackwell and Weintraub, 1990). Moreover,
the MyoD-E47 heterodimer favors a DNA-binding site comprising the
separate half-sites of the Myol) and E47 homodimers rather than a
new whole site. Thus, the pairing of Myol) with different bHLH
21
proteins may be a means to discriminate between different E-box
sites.
In summary, the activity of myogenic proteins are subject to
the control of a number of bHLH and non-bHLH proteins through
direct interactions, the DNA binding activity of the myogenic
proteins themselves is dependent on protein-protein interactions,
and through binding to different DNA sites, the myogenic proteins
directly control the expression of a number of muscle specific
genes, and other genes as well Myol) has recently been shown to
bind to the enhancer element of the c-fos promoter and by so doing,
block the transcription of the c-fos gene (Trouche et al., 993) ].
For the family of myogenic proteins, of which Myol) is one of the
best studied members, many of the protein-protein and all of the
protein-DNA interactions are mediated by the bHLH domain.
Extensive biochemical and genetic studies have shown that the
basic region of the bHLH motif contacts the DNA, while the HLH
region is responsible for oligomerization (Davis et al., 990). For
Myol) and the other myogenic proteins, there is a particularly rich
supply of mutagenesis data which documents the role of many of the
amino acids contained within the bHLH domain (Davis et al., 1990;
Brennan et al., 99 1; Winter et al., 992). Residues important for
DNA binding, and oligomerization, as well as for transcriptional
activation have been determined by these studies. Sequence
homology among the bHLH domains across a wide spectrum of
eukaryotic proteins suggests that the tertiary fold of the bHLH
domain would be fairly well conserved.
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When we began our studies, there was little known about the
tertiary structure of bHLH (or bHLH-ZIP) domains. Since it was
known that bHLH and bHLH-ZIP domains bound DNA as dimers, many
of the initial models of these proteins were based on four helix
bundles. Some of these models had parallel bundles (Anthony-Cahill
et al., 1992; Vinson and Garcia, 1992; Halazonetis and Kandil, 1992;
Davis and Halazonetis, 1993), while other models featured anti-
parallel bundles (Starovasnik et al., 1992; Gibson et al., 1993).
Since little was known about the structure of the bHLH domains, and
since there was a wealth of biochemical and genetic data on MyoD
and the other myogenic proteins, we had strong motivations to
undertake structural studies of the Myol) bHLH domain. We hoped
that a detailed structure of the Myol) bHLH domain bound to DNA
would provide a framework for answering three important struc-
tural questions concerning the bHLH family of proteins: 1 How does
the bHLH basic region distinguish between different E-box sites; 2)
How does the bHLH dimerization region distinguish between
different oligorneric partners and what stabilizes these dimeric
interactions; 3 How might the structure of the bHLH domain
contribute to transcriptional activation and how does the structure
of the Myol) complex explain the biochemical and genetic data on
transcriptional activation in myogenic proteins?
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CHAPTER 2
Crystallization of a MyoD/DNA Complex
32
Crystallization of the Myol) bHLH-DNA complex presented a
number of challenges. The first part of this chapter describes how
microheterogeneity in the protein samples (Lorber and Gieg6, 992)
was tested for and when discovered, how steps were taken to
reduce or eliminate these problems. The second part of this chapter
describes the survey of different conditions and DNA sequences in
the successful cocrystallization of Myol) bound specifically to DNA.
We found that varying both the length and the sequence of the DNA
(Jordan et al., 1985), particularly at the 5' and 3 ends, was
essential for obtaining the diffraction quality crystals used in the
structure determination. Finally, the third part of the chapter
describes the packing arrangements in the asymmetric unit of the
MyoD-DNA cocrystal. The packing arrangement seen in our MyoD-
DNA crystals is different from that seen in most other protein-DNA
cocrystals which have the DNA duplexes stacking end-on-end to
generate a pseudo-continuous helix (Jordan et al., 1985). The
distinct crystal packing seen in the MyoD-DNA complex provides a
possible explanation of why the initial selection of DNA sequences
for the crystallization trials was unsuccessful and underscores the
importance of testing a variety of different DNA sequences in
crystallization trials of protein-DNA complexes.
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A. Analysis, Preparation, and Purification of MyoD and DNA
1. bacterial strains and plasmids
The E coft expression host BL21 (DE3) contains the plasmid
pLysS in order to express low levels of T7 lysozyme and thus,
stabilize plasmids under the control of an inducible promoter for 7
polyrnerase (Studier, 9 91 ). The expression plasmid pRK 1 71 a
(McLeod et al., 1987; Figure 1) contains a restriction site polylinker
downstream of a phage T7 promoter. Deletion and truncation
mutants of MyoD which contained the bHLH region (Tapscott et al.
1988, Harold Weintraub, personal communication) were subcloned
into the polylinker of pRK1 71 a. All plasmids, subclones and
expression hosts used in our studies of MyoD were provided by
Harold Weintraub.
2-Oven on and Purification of MygD bHLH Domain
The MyoD fragments which we used in our crystallization
studies all contained the bHLH domain and were derived from the
MyoD deletion mutant DM:4-1 01;TM:1 67 (Tapscott et al., 1988). The
initiator ATG of this mutant was engineered to form part of an Ndel
site, while the termination codon formed part of a HindIll site so
that the MyoD fragments could be subcloned into the appropriate
sites of the polylinker of pRK1 71 a. We used five different MyoD
peptide fragments (provided by Harold Weintraub) in our studies
(Figure 2). The first of these fragments comprised 68 amino acids
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and contained the entire bHLH region from mouse Myol) (residues
102 to 166), along with the three amino acids Met-Glu-Leu at the N-
terminus. The second and third fragments of MyoD were based on
the first and were made in order to avoid oxidation problems (see
below). These fragments contained a C1 35Y and a C1 35S
substitution respectively. The fourth and fifth fragments were
identical to the second and third except that they were shorter at
the N-terminus by amino acids; hence they contained residues 108
to 166, along with an N-terminal Met for a total length of 60 amino
acids. All five fragments of Myol) were tested for DNA binding
activity by gel shift experiments. The fragment which we used in
our final crystals was the 68 residue peptide with the C1 35S
substitution (MD-bHLH'Cl 35S).
Cells containing the pRK1 71 a plasmid with the MyoD inserts
were grown at 37 in LB broth containing ampicillin 200,pg/ml)
and chloramphenicol (50 jig/ml). When the A600 reached 0.5,
expression of the protein was induced by adding IPTG (isopropyl
P-D-thiogalactopyranoside) to 0.5 rnM in order to induce expression
of the T7 RNA polymerase which in turn started the expression of
the bHLH fragment. Three hours after the IPTG induction, the cells
were harvested, resuspended in lysis buffer 25 mM HEPES, pH 76, 1
mM EDTA, 5 mM DTT, 200 rnM NaCl, 1 mM PMSF (phenylmethyl-
sulfonyl fluoride), ug/ml pepstatin, 1 pg/ml benzamide, 1 pg/ml
leupeptin, 1 0% (v/v) glycerol), and lysed by repeated freeze-
thawing and sonication. After collecting the supernatant of the
centrifuged cells, polyethyleneimine (PEI) was added to a final
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concentration of 07% in order to partially purify the protein from
the cellular DNA. After spinning down the PEI precipitate, the
supernatant was brought to 06 M ammonium sulfate over the course
of hour while stirring at 4 C. The pellet from this precipitation
was resolubilized in ysis buffer w/o glycerol and dialyzed against
the same solution in preparation for column chromatography.
Two reversed-phase HPLC chromatography steps were used to
purify the MyoD peptides. For the first step, the resuspended and
dialyzed ammonium sulfate pellet was loaded onto a Vydac C4
preparative column 2.2 x 2 .0 cm), 1 0,um particle size. The
protein was eluted with a gradient of to 95% acetonitrile/0. 1 %
trifluoroacetic acid (TFA) at a column temperature of 40 C. The
protein usually eluted at around 40% acetonitrile. The eluate was
then dialyzed successively against lysis buffer and distilled water
and concentrated by partial yophilization (being careful not to
1yophilize to dryness). Several steps were taken at these stages to
guard against oxidation of the protein (for the C1 35Y and C1 35S
mutants, these steps were not necessary). First, immediately after
collecting the protein fractions from the reversed phase columns,
DTT was added to a final concentration of mM before freezing the
eluates in a dry ice/ethanol bath. DTT was also present in all of the
dialysis solutions, and whenever possible, yophilization was done
in an anaerobic chamber with < PPM Of 02 (Coy Laboratory
Products, Grass Lake, MI). For the second reserved-phase
chromatography step, we used a Vydac C18 semi-preparative column
(1-0x25.0cm),5-pmparticIesize. Theelutiongradientwas
similar to, but more shallow than that used with the first reversed-
phase column. After dialysis and concentration of the eluate from
this second chromatography step, the protein was judged to be
greater than 98% pure as judged by SDS gel electrophoresis (single
band on an overloaded silver stained gel).
3. Synthesis and Purification of liaodeoxyribonucleotides
We used the solid-phase phosphoramidite method on an
Applied Biosystems (Foster City, CA) model 392 DNA/RNA
synthesizer for producing all of the oligodeoxyribonucleotides
(oligonucleotides) in our studies. We generally used 1 lim and
1 pm columns from Applied Biosystems, as well as the
manufacturer's chemicals and protocols. We did not remove the -
dimethoxytrityl (DMT) protecting group after the last cycle in order
to aid in purification of the oligonucleotide. The purification of the
DNA was a modification of a protocol previously described (Jordan
et al., 1985) involving two chromatographic steps of reversed-
phase HPLC. In the first step, each strand of DNA is purified with
the DMT group attached. Since many of the oligonucleotides used in
our studies were symmetrical or close to symmetrical, we took
care to perform all chromatographic steps at 50 C in order to
destabilize unwanted secondary structure. After the first
chromatography step, the DMT group was cleaved with a brief acid
treatment (1 0 minutes) at room temperature using trichloroacetic
acid 1.1%, pH 1.5). To protect against acid depurination of the DNA,
we stopped the acid treatment with the addition of triethylamine,
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and then immediately dialyzed the solution against 1 0 mM
triethylammonium bicarbonate (pH 70) followed by distilled water,
before yophilizing the sample. The second reversed phase HPLC
step was done after the DMT group had been removed. After the two
chromatography steps, we annealed the separate DNA strands into
duplexes. As mentioned previously, many of the oligonucleotides
used in our studies were self-complementary. In order to prevent
the formation of hairpins, we performed the annealing steps at a
high oligonucleotide concentration (about 3 mM) so as to-drive the
formation of duplexes versus hairpins (Joachimiak and Sigler,
1 99 
Oxidation of Cysteines in MyoD
Previous attempts to crystallize the MyoD-DNA complex
resulted in a number of crystals, all of which failed to diffract
(Beishan Liu and Carl Pabo, unpublished results). Before starting
the next round of crystallization, we wanted to determine if there
were any systematic microheterogeneities in the protein and/or
DNA samples which may have prevented the formation of diffraction
quality crystals. Formation of disulfide bonds may disrupt normal
folding, oligomer contacts, or preferred crystal packing
arrangements (Van der Laan et al., 989; Pavletich and Pabo, 991).
The bHLH domain of mouse MyoD contains a cysteine residue at
position 135, which is at the C-terminus of the helix 1. In order to
determine if oxidation may have been contributing to heterogeneity
in our crystals, we dissolved some previously grown crystals of the
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MyoD-DNA complex (Beishan Liu, personal communication) and by
running the protein products on an SDS gel determined that some of
the MyoD peptide had formed a covalent dimer.
Problems with oxidation of the MyoD bHLH peptide have been
corroborated in a recent NMR study of MyoD (Starovasnik et al.,
1992). The NMR study used a fragment of MyoD which was identical
to our MD-bHLH fragment (Figure 2. In the study, the authors were
unable to determine an NMR structure of reduced MyoD, but were
able to determine the structure of an oxidized homodimer of MyoD
covalently linked through a disuffide bond between Cysl 35 residues
from each monomer. The oxidized MoD peptide was tested for DNA
binding activity and this was found to be reduced by 1 00-1 000 fold.
Unlike our crystallization studies with MyoD, the NMR study only
involved the MyoD bHLH peptide alone and not the complex of MyoD
bound to DNA. In the NMR study, the authors proposed an
antiparallel four helix bundle structure for the oxidized MyoD
homodimer which was markedly different from the parallel four
helix bundle structure seen in the cocrystal structures of the bHLH-
ZIP domain of Max bound to DNA (Ferr6-D'Amar6 et al., 1993), the
bHLH domain of USF bound to DNA (the leucine zipper, which is
normally present in this bHLH-ZIP protein, was deleted for
crystallization purposes; Ferr6-1)'Amar6 et al., 1994), the bHLH
domain of E47 bound to DNA (Ellenberger et al., 1994), and the bHLH
domain of MyoD bound to DNA. The antiparallel four helix bundle
structure of the oxidized MyoD homodimer is incompatible with the
mode of DNA binding seen in the three cocrystal structures. We
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presume that the antiparallel structure is an artifact of the
disulfide bonds, and we do not believe that it is biologically
relevant.
After concluding that oxidation of the MyoD peptides would be
a serious impediment to obtaining diffraction quality crystals, we
took several approaches to avoid oxidation of the MyoD peptide At
first, we tried to grow our cocrystals of MyoD in an anaerobic
chamber with. < PPM Of 02 (Coy Laboratory Products, Grass Lake,
MI). Growing the MyoD-DNA crystals under these conditions
produced crystals which diffracted, albeit weakly (Table 1. Since
it was experimentally awkward to set up a very large number of
crystallization trials in the anaerobic chamber, we soon switched
to using the MyoD fragments MD-bHLH-C1 35Y and MD-bHLH-Cl 35S
(provided by Harold Weintraub; Figure 2 in our crystallization
trials. As mentioned above, the replacement of the cysteine by
tyrosine and serine did not alter the DNA binding activity of the
Myol) bHLH peptide, as measured by the gel shift assay. We note
also that among the myogenic proteins, there is a fair amount of
diversity in the identity of residue 135, suggesting that there may
not be strong functional constraints on the identity of this residue.
In fact, one of the two forms of MyoD from Xenopus has a tyrosine
at position 135, while myogenin 77% identity with MyoD in the
bHLH region) has a serine at this position.
5. Probing for Proteglysis and- Eost-Synthetic Mgdif icat
Aside from the oxidation of cysteines, we searched for other
common sources of microheterogeneity such as partial proteolysis.
We used several independent analytical techniques to probe for
possible contaminants and microheterogeneities in our MyoD
peptides. All of the MyoD peptides which we tested in our
crystallization studies were judged to be pure by SDS gel
electrophoresis: the samples gave a single band on an overloaded
silver stained gel. With the help of Jonathan Weissman (M.I.T.) we
also tested the C1 35S-substituted peptides by capillary zone
electrophoresis on an Applied Biosysterns machine (Foster City, CA)
which indicated that the peptides were homogeneous (Figure 3.
Electrospray mass-spectroscopy, amino acid composition analysis
and N-terminal sequencing were also performed on the MyoD
peptides (William Lane, Harvard University). These tests suggested
that there were no serious problems of proteolysis or postsynthetic
modifications in our C1 35Y and C1 35S substituted MyoD peptides.
6. Flexible Regions in the.-MyoD bHLH Domain
Even when proteins are judged to be free of oxidation,
proteolysis or post-synthetic modifications, problems in
crystallization may still occur due to the presence of flexible
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regions in the protein. These flexible regions may significantly
increase the degrees of conformational freedom for the protein and
prevent the formation of well-ordered crystals. In the NMR studies
of MyoD, the flexibility that was present in the reduced peptide of
Myol) (but not in the oxidized homodimer) prevented the
determination of the tertiary structure for the MyoD peptide
(Starovasnik et al., 1992). For the UIP DNA binding domains found
in proteins such as GCN4, fos, jun, and C/EBP there is considerable
evidence to suggest that much of the domain is unstructured in the
absence of DNA, but upon DNA binding, there is an induction of
alpha-helical structure (O'Neil et al., 1990, 1991; Weiss et al.,
1990; Patel et al., 1990). Given that both the bIP and the bHLH
domains consist of a basic region attached to a dimerization motif,
we wanted to test if there were any flexible regions in the bHLH
domain and if so, would the flexible regions in the bHLH domain
become better ordered when the bHLH domain was bound to DNA.
We used circular dichroism (CD) spectroscopy to look at the
interaction of the MyoD bHLH domain with an oigonucleotide
containing its specific DNA-binding site. With the help of Susan
Marquese (who had been in Robert Sauer's laboratory at M.I.T.) we
took CD spectra of the MyoD bHLH peptide in the absence and
presence of the DNA probe. CD spectra were taken on an Aviv model
6ODS spectrapolarimeter. For the protein sample, we used purified
MD-bHLH at 5.5 jM concentration (quantitated by measurement of
A205 in 25 mM potassium phosphate (pH 70), 50 mM potassium
chloride, 01 mM EDTA, and 02 mM DTT (to prevent oxidation of
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MyoD). The DNA sample was a 21 base pair oligonucleotide at 5.5
pM concentration, purified according to the methods listed above
and containing the sequence 5' ATAGTAGACAGCTGTCCCAAC 3 on one
strand, and the sequence 5' TGTTGGGACAGCTGTCTACTA 3 on the
other strand (we had used this oligonucleotide in our crystallization
trials; Table 1). In the MyoD/DNA samples, we mixed .5.uM of MyoD
with 55 pM of DNA (thus, the DNA was added at 2-fold molar excess
to dimeric protein). Both the DNA samples and the MyoD/DNA
samples were in the same buffer as that of the MyoD peptide alone.
CD Spectra were taken at 25 T using a mm path-length cell, 1.5
nrn bandwidth, 1.0 average time per point, and 0.5 nm scan steps.
Measurements were taken over a range of 200 to 350 nm. We did
not perform smoothing on the measurements. For all measurements,
we subtracted a baseline spectra of the CD sample buffer.
Our CD measurements showed that the 68 amino acid MyoD
peptide in the absence of DNA showed only a modest alpha-helical
content (Figures 4 and 5). We measured the molar ellipticity at 222
nm, and estimated the fractional helix contents from 0222
measurements, using the formula 40,000(1-2.5/n) to represent
1 00% helix (n is the number of amino-acid residues in the peptide),
and 0222 to represent 0% helix (Chakrabartty et al., 991 ). For
the MyoD peptide alone, 0222 = 3251 deg CM2/dmol which is
consistent with an estimated helical content of 34%. When we
added the DNA probe in 2-fold molar excess to the MyoD, and then
subtracted the DNA spectrum from the MyoD-DNA spectrum (Figures
4 and 5), we got a 0222 value of 33,977 deg cm2/dmol, which is
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consistent with an estimate of 88% helical content. Interestingly,
an independent CD study of a MyoD bHLH peptide gave a
0222 of -1 4,000 deg CM2/dmol for the peptide alone at pM, and a
0222- of 30,000 deg CM2/dmol when a 12 fold excess of a DNA
probe was added to the peptide (Anthony-Cahill et al., 1992).
Significant inductions of alpha-helical structure in bHLH-ZIP
proteins upon specific binding of DNA have also been reported
(Fisher et al., 1993; Ferr6-1)'Amar6 et al, 994). Our results, plus
those of others, demonstrate that there is significant flexibility in
the basic region of Myol). Our CD studies have shown that the fold of
the bHLH region is significantly different in the presence and
absence of DNA. In addition to the interest of this result by itself,
our solution CD studies of MyoD also suggested to us that it would
be difficult to grow well-ordered crystals of the Myol) bHLH domain
in the absence of DNA (and may perhaps explain why it was so
difficult to obtain good NMR spectra of My oD peptide when it was
not in an oxidized homodimer form (Starovasnik et al, 1992) ) In
contrast, our CD studies suggest that when Myol) is bound to DNA,
much of the bHLH peptide has an ordered alpha-helical structure.
This suggested to us that we should be able to obtain well-ordered
crystals of the protein-DNA complex given the appropriate DNA site
and the absence of significant microheterogeneities.
0. Crystallization of the MvoQ-DNA complex; Thg Effects of
Systgmatic Variation in DNA equence and enath
The sequence and length of the DNA used in cocrystallization
trials have been shown to have significant effects on the quality of
the cocrystals produced (Anderson et al, 1984; Jordan et al., 1985,
Schultz et al, 990; Liu et al., 990; Wolberger et al., 991 a In
most protein-DNA cocrystals (the lambda cro represssor-operator
complex is one of the few exceptions (Brennan et al., 1990) ), the
DNA segments stack end on end to form a continuous or pseudo-
continuous helix (Jordan et al., 1985). In order to maximize the
chances that the DNA sequences have a repeating unit in the crystal
which is consistent with the 1 0.5 base pairs per helical turn that
DNA has in solution, many oligonucleotides in cocrystallization
studies have lengths which are consistent with having an integral
or half-integral number of helical turns in the DNA (Anderson et al.,
1 984; Jordan et al., 1 985). One study showed that differences in
the DNA length of as little as one base pair can dramatically effect
the quality of the crystals (Jordan et al., 1985). The same study
suggested that the sequence identity at the ' and 3 ends of the DNA
can have a large effect on crystal quality. In particular, the study
recommended that DNA fragments with one or two complementary
overhanging nucleosides at the 5' and 3' ends would stabilize end on
end stacking of the DNA segments in a pseudocontinuous helix, and
thus, help provide stable crystal contacts. Our cocrystallization
trials with MyoD strongly confirm the importance of testing a
variety of different DNA sequences and lengths. One surprise from
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our studies, however, was that the DNA packing contacts in our
final crystal did not follow the usual end on end, pseudocontinuous
DNA helix pattern seen in other crystals. Thus, our
cocrystallization studies of MyoD may be of some general relevance
to the problem of cocrystallizing protein-DNA complexes. This idea
will be discussed in more detail in the section describing the
crystal packing contacts in our structure.
1. Selection gf DNA Sites and Results of Coc[ystallization Trial
In all, we tested 34 different DNA sequences in our
cocrystallization trials with MyoD (Table 1). We were able to
obtain crystals with most of the DNA sequences tested, and we
tested many of these crystals for X-ray diffraction. A number of
these crystals diffracted, but only a few of these crystals gave
relatively ordered diffraction patterns. Our structure was
determined from the crystal which diffracted to the highest
resolution even though the unit cell size of this crystal suggested
that there were several complexes in the asymmetric unit (a =
222.8 A, b = 70.8 A, c = 30.0 A, P21212 space group; see Chapter 3
for further discussion of structure determination). In our first
crystallization experiments, we tried to reproduce the results of
previous crystallization trials with Myol) (Beishan Liu and Carl
Pabo, unpublished results). In these earlier experiments,
crystallization attempts with MyoD (which was probably partially
oxidized) and the oligonucleotides D21 -1 and D21-2 gave crystals
which did not diffract. After we had determined that oxidation of
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the cysteines was a potential problem with crystallization, we
tried to grow crystals of reduced MyoD with the D21 -1 and D21-2
oligonucleotides in an anaerobic chamber. We were unable to obtain
crystals of Myol) with these oligonucleotides under conditions
similar to those which gave crystals in an air oxidizing
environment, thus raising the possibility that the partial oxidation
of MyoD substantially changes the crystal packing contacts and/or
folding arrangement of the peptide. At this point, we decided that
in addition to performing crystallization trials under anaerobic
conditions and/or using the C1 35Y and C1 35S substitutions, we
would test a greater variety of DNA sites. We based the design of
our DNA sites on recent binding site selection experiments on Myol)
which suggested that the optimal binding sites for the MyoD
homodimer would be a symmetrical site based on the sequences '
AACAGCTGTT 3 or 5' GACAGCTGTC 3 (Figure of Chapter 4;
Blackwell and Weintraub (1 990); Blackwell and Weintraub,
unpublished results).
The binding site selection experiments suggested that the
MyoD homodimer contacted a region spanning at least 
nucleotides, and thus, we planned to test oligonucleotides which
had DNA binding sites of at least that length. Our first DNA sites
were designed to have an integral number of helical turns, and had
overhanging ends with one or two complementary nucleosides in
order to promote formation of a pseudocontinuous helix (M21-2,
M20-2, M21-3, M20-3 in Table 1). We were able to grow cocrystals
in the anaerobic chamber with all four of these DNA sites, but these
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crystals diff racted quite poorly. We also realized that although the
central bases of CAGCTG were symmetric within these four DNA
sites, the flanking base pairs were not perfectly symmetric. Thus,
overall, the four DNA sites were only pseudo-symmetric and not
perfectly symmetric. While this lack of perfect symmetry may not
have significantly affected binding of the Myo!) peptide to the DNA
sites, it was a potential source of crystallographic disorder.
Previous crystallization studies had indicated that nearly
symmetric DNA sites may crystallize in two different orientations
in the unit cell, where one orientation of the DNA differs from that
of the other by a 1 80' rotation through the pseudo-dyad axis of the
nearly symmetric DNA (DiGabriele et al., 1989; Wolberger et al.,
1991 b) A mixture of two different orientations for the DNA in the
unit cell may be a source of crystallographic disorder, and thus, we
were concerned that the four DNA sites M21-2, M20-2, M21-3, and
M20-3 gave poorly diffracting cocrystals because of disorder
arising from pseudo-symmetric DNA sites. In the rest of our
crystallization trials, then, we chose DNA sites that were perfectly
symmetric, or would result in repeating units that were perfectly
symmetric, or which had sufficient asymmetries in the flanking
bases such that we expected the DNA helices to pack in a unique
direction in the crystal. We tested three oligonucleotides that had
significant asymmetries in the flanking bases (M22-1, Ml 4-5, and
Ml 4-9 in Table 1). Only one of these oligonucleotides, M22-1, gave
cocrystals and these were of poor quality. We therefore decided to
concentrate on symmetric oligonucleotides or asymmetric
oligonucleotides that would generate symmetric repeating units.
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One of the problems with using perfectly symmetric
oligonucleotides for crystallization studies is that one can not
easily vary the spacing between adjacent DNA binding sites without
changing the length of the oligonucleotide. With an asymmetric
oligonucleotide of any given length, it is possible to form a number
of repeating units that have different spacings between adjacent
DNA binding sites. With a symmetric oligonucleotide of the same
length, however, one cannot change the spacing between adjacent
DNA binding sites unless 1) the symmetric oligonucleotide is long
enough to accommodate 2n number of sites with spacing between
the sites, or if 2 adjacent sites within the symmetric
oligonucleotide are allowed to overlap. For MyoD, with its binding
site of at least ten bases, the first condition above would be
difficult to satisfy for practical reasons (synthetic DNA sites
greater than 20 base pairs are difficult to purify), while satisfying
the second condition could bring back the problems of alternate
packing in the crystal (MyoD could bind to either one of two
overlapping sites, and a mixture could result in the crystal).
In order to circumvent some of the limitations of using
symmetric oligonucleotides in crystallization trials, we designed a
series of asymmetric oligonucleotides which would nevertheless
generate a repeating unit that was symmetric because the
asymmetric oligonucleotides contained 2 base pair overhangs which
were two-fold symmetric (Figure 6 All of the oligonucleotides
tested in this series (M21-5, M20-5, M22-2, M21-6, M21-7 in Table
1) contained a 12 base pair symmetric DNA binding site for MyoD: '
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C-AACAGCTGTTG 3 Our design of these oligonucleotides allowed for
variation of the spacings between adjacent 12 base pair binding
sites within an oligonucleotide of a given length (compare M21 5
With M21-6 and M21-7 in Table 1; Figure 6 These spacings
between, adjacent binding sites had a big effect on crystallization
since we were only able to obtain cocrystals with the
oligonucleotide M21 -5, and not with the four other oligonucleotides
in the series. Unfortunately, the MyoD/M21-5 crystals did not
diffract well, indicating that there was still substantial disorder
within these crystals.
While we were testing the strategy of using asymmetric
oligonucleotides with two-fold symmetric overhangs, we also
tested a series of perfectly symmetric oligonucleotides for
cocrystallization trials (M 1 0-2, M 1 2- 1, M 1 4- 1, M 1 4-2 in Table 
We, obtained cocrystals with the 14 base pair oligonucleotides;
these were of the best quality of all the cocrystals tested to that
point. We collected low resolution data sets from both the Ml 4-1
and
Ml 4-2 cocrystals, but were unable to grow cocrystals with these
oligonucleotides which diffracted beyond 3.5 to 4 A resolution. The
Ml 4-1 oligonucleotide had a two base pair complementary overhang,
whereas the Ml 4-2 oligonucleotide was blunt ended. Since we were
able to obtain modestly ordered cocrystals with both of these
oligonucleotides, we decided to test 14-mer and 15-mer
oligonucleotides with different sequences at the flanking bases. in
partcular, we wanted to optimize the crystal packing of the DNA by
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systematically testing different types of DNA termini: 1 blunt
ends, 2 complementary overhangs, 3 blunt-ends with mismatches
at the termini, 4 non-complementary overhangs which are identical
on the top and bottom strands; these overhangs could not form
Watson-Crick base pairs, but could potentially interact with a base
pair at the end of a neighboring helix to form a base triplet
arrangement at the junction of the DNA helices (Schultz et al.,
1 990; Luisi et al., 99 1 ). In addition to M 1 4-2, oligonucleotides in
thefirstcategoryincludedMl4-6,Ml4-7,Ml4-8,Ml4-1l,and 
Ml 4-12. The second category contained the previously mentioned
M14-1,alongwithM`15-4. TheoligornersM14-13andM14-14were
in the third category while the fourth category contained Ml 4-3,
M14-4,MlS-1,MlS-2,MlS-3,Ml5-5,andMl5-6.
Our best cocrystals were grown with oligonucleotides from
the first category: symmetric 14-mers with blunt ends. The quality
of crystals was very dependent on the identity of the base pairs at
the DNA termini. Thus, cocrystals grown with oligonucleotides
containing C-G base pairs at the ends, such as Ml 42, Ml 47, and
Ml 41 1, differed considerably in morphology and diffraction quality
from cocrystals grown with oligonucleotides containing A-T base
pairs at the ends, such as Ml 46, Ml 48, and Ml 412. Moreover, the
effect on crystallization of the sequence identity at the DNA
termini was not limited to a simple C-G base pair versus A-T base
pair difference. The identity of the individual nucleosides at the '
and 3 termini had a significant effect on crystal quality. Thus,
Ml 42, which had a C at its 5' end and a G at its 3 end gave better
cocrystals than Ml 47 and Ml 41 1, both of which had G's at their '
ends and C's at their 3 ends. Ml 41 2 gave the best crystals of all,
with a T at the ' end and A at the 3 end; Ml 46 and Ml 48 which
had the identities of the ' and 3 ends exactly reversed from those
of Ml 41 2 gave significantly poorer crystals. It is interesting that
a number of studies which have used quantum mechanical methods
to calculate stacking energies of different base pairs predict that
stacking of adjacent C-G base pairs should be more energetically
favorable than stacking of adjacent A-T base pairs (Saenger, 984;
Kudritskaya and Danilov, 976; Ornstein et al., 1978 ). It may be
significant that our best crystals came from a blunt-ended
oligonucleotide, Ml 41 2 that would be predicted to have rather
weak stacking energy. We shall see later on in this chapter how
weak stacking energies between adjacent DNA's may have
contributed to the particular crystal packing arrangements seen in
our structure.
2. Crystallization Using Different MyoD Pel2tide Fragments
During the course of our crystallization experiments, we tried
several different peptides, and also tried peptides with
substitutions for the Cys 135. The Cl 35Y and Cl 35S substitutions
which we used in our crystallization studies substantially widened
the range of crystallization conditions we could test since the
substitutions allowed us to work outside of the anaerobic chamber.
We were able to grow cocrystals with the substitution mutants, as
well as with the original Myol) peptides under anaerobic conditions.
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The cocrystals were of similar quality, although cocrystals grown
with the C1 35S substituted MoD appeared to give slightly better
quality crystals Qudged by visual appearance) than the Cl 35Y
substituted crystals. Thus, we performed most of our
crystallization trials with the Cl 35S substituted MyoD peptides In
addition to the substitutions at the Cys 135 residue, we also tested
the effects of shortening the MyoD bHLH peptide at the N-terminus.
Sequence comparisons with other bHLH and bHLH-ZIP proteins
(Murre et al., 1989), along with mutational analysis on the MyoD
bHLH region (Davis et al., 990) suggested that the residues N-
terminal to Ala 108 were not necessary for the function of the bHLH
region. We thus tested the two MyoD peptides sMD-bHLH-C1 35Y and
sMD-bHLH-C1 35S (Figure 2, which were shorter than our original
bHLH peptide by residues, in crystallization trials. We were
unable to grow good crystals with the shorter peptides, and thus,
we concentrated on using MD-bHLH-Cl 35S as the main MyoD peptide
in our experiments. (Later analysis showed that the N-terminal
residues formed critical crystal packing contacts.)
.3. Conditiol]s fr Ccystallizations
We were able to grow cocrystals of MoD from a variety of
crystallization conditions. The best conditions appeared to vary
with the oligonucleotide used for the cocrystallization. Thus, the
best crystals for cocrystals grown with Ml 4-1 were grown at 4 T
in 5-1 0% polyethylene glycol (PEG) 3350, 1 00 mM Malonic Acid, pH
5.5, 20-200 mM MgCI2, and 50-1 00 mM NaCl or Na3 Citrate. The
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cocrystals grown with Ml 42 grew at room temperature over a
narrow pH range (5. - 60). There was no need to add precipitating
agents in order to grow crystals. Instead, crystals grew directly
out of an amorphous precipitate formed when the Myol) peptide was
added to DNA. The crystals grew with a variety of buffers: citrate,
acetate, Bis-Tris, malonate, succinate, MES, and cacodylate, but the
best crystals grew with citrate or MES. The rate of crystal growth
was controlled by using volatile buffers in hanging drop
experiments or by growing crystals in microdialysis buttons.
Crystals grown with Ml 4-1 2 were of two forms: 1 a monoclinic
form that grew out of crystallization conditions similar to those
used in cocrystallizing Myol) with Ml 4-2, that is, vapor diffusion of
volatile buffers to generate a pH gradient and 2 an orthorhobmic
form that grew out of 10-1 5% PEG 4000, 1 00 mM Tris, pH 8.5, 1 00
mM NaCitrate, 20 mM BaC12 at room temperature; our structure was
determined from the orthorhornbic crystal form. It may be
significant that out of the four crystal forms from which data were
collected, the three monoclinic forms (for Ml 4-1, Ml 4-2 and Ml 4-
12) were all grown at relatively low pH values (5 to 6 whereas the
orthorhombic crystal form, which diffracted the best, grew at
relatively high pH values (8 to 8.5). Thus, out of all of the possible
variables in crystallization conditions (aside from the identity of
the DNA oligomer), it would appear that the pH probably played the
most significant role in obtaining well-ordered cocrystals of'MyoD,
consistent with the notion that the pH is one of the most important
factors in the crystallization of macromolecules (Zeppenzauer,
1971; McPherson, 1982).
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4. Effects of Salts and Additives on C[ystallizat
All of the MyoD cocrystals grew out of relatively low salt
concentrations (usually < 00 mM). The identity of the salt used
was fairly important: in most cases, using Na Citrate helped to
improve the quality of the cocrystals. Aside from Na Citrate, other
additives did not have much of an effect on the quality of the
crystals. Divalent cations, such as MgCI2, CaCI2, and BaCI2 were
usually tested when screening crystallization conditions since
previous studies of protein-DNA complexes had shown the
importance of multivalent cations in influencing the quality of the
crystals formed (Joachimiak et al., 1987; Wolberger and Harrison,
1987; Schultz et al., 1990). In our crystallization trials with Myol),
we found that although the presence of divalent cations appeared to
improve the quality of the crystals in some cases, the marginal
improvement which they added was small. Other common additives
in crystallization studies such as glycerol, MPD, spermine, and n-
Octyl-beta-D-glucopyranoside had no significant effect on the
quality of our cocrystals.
C. Packing Contacts in the Mvol) Cocrystals
Solution of the crystal structure (see Chapters 3 and 4)
revealed that the crystal packing contacts in the unit cell of the
MyoD-DNA structure do not involve end on end stacking of the DNA's
to generate a pseudocontinuous helix (a packing arrangement which
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is commonly seen in protein-DNA complexes (Joachimiak and Sigler,
1991) ). The asymmetric unit of the crystal contains two copies of
a Myol) bHLH dirner bound to a 14 bp DNA site (Figure 7 Within this
asymmetric unit, the two blunt ended DNA oligomers stack against
each other. In the context of the unit cell, however, the ends of the
DNA oligomers pack against the Myol) protein, as well as against the
ends of other DNA oligomers (Figure 8). Specifically, the end of one
DNA helix packs against helix 2 and the loop from a Myol) protein in
a neighboring asymmetric unit (Figure 9 The DNA-DNA and DNA-
protein packing contacts, as well as a number of protein-protein
contacts, together comprise a complicated network of packing
contacts in our crystal (Figure 8). It is interesting that the Max
bHLH-ZIP-DNA cocrystal also has a rather intricate packing
arrangement for the protein and the DNA; as with the Myol)
cocrystal, the DNA in the crystal of the Max complex does not form
a pseudocontinuous helix (Ferrd-D'Arnar6 et al., 1993).
The elaborate packing arrangements seen in our crystal and
that of the Max complex may have been due, in part, to the extensive
solvent accessible surfaces found in the bHLH and bHLH-ZIP
structures. These structures have long, extended alpha-helices
oriented essentially perpendicular to the DNA helical axis, and thus,
are significantly different from the more compact globular
structures seen in the helix-turn-helix, homeodomain, and zinc
finger family of DNA-binding domains (Jordan and Pabo, 1988;
Kissinger et al., 1990; Pavletich and Pabo, 991 ). Another factor
which may have contributed to the packing schemes seen in the
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Myol) and Max crystals, is the nature of the blunt-ended DNA
ofigomers found in the two crystals. As discussed earlier, the
crystallization of the Myol) complex was very dependent upon both
the length and sequence of the DNA sites used in the crystallization
trials. We needed to test a large number of different DNA sites
before we obtained well-diffracting crystals. The intricate packing
scheme seen in our final crystal is consistent with a strict
requirement for both DNA length and sequence. In particular, we
note that the packing of one end of a DNA helix against helix 2 and
the loop of a Myol) peptide from a neighboring asymmetric unit
(Figure 9 would not be predicted to be as favorable if the ends of
the DNA helices had overhanging ends; complementary Watson-Crick
and/or triple helix interactions formed by these overhanging ends
would promote end on end stacking of DNA duplexes from
neighboring asymmetric units (Jordan et al., 1985, Otwinowski et
al., 1988).
Overall, our experience with the cocrystallization of Myol),
together with an analysis of the packing seen in the final crystal,
reinforces the importance of testing a large variety of different
DNA sites in cocrystallization trials for protein-DNA complexes.
We note, with some humility, that in spite of our attempts to
rationally design the DNA sites so as to optimize crystal packing,
the final packing scheme for our crystals was quite unexpected. We
had originally designed our 14 bp DNA site to have a half-integral
number of turns in the DNA (Anderson et al., 1984; Jordan et al.,
1985), so that the DNA oligomers would stack end on end in a
57
pseudo-continuous helix. The Max complex had a 22 bp DNA site in
the cocrystal (Ferr6-D'Amard et al., 1993) which, like the MyoD
cocrystal, did not have the DNA pack in a pseudo-continuous helix.
The unexpected crystal packing schemes seen in the MyoD and Max
cocrystals illustrate the diversity of packing arrangements in
crystals of protein-DNA complexes. It may be the case that the long
extended alpha-helices found in the bHLH and bHLH-ZIP structures
make it especially difficult to rationally design oligonucleotides
for crystallization. In this regard, we note that the crystal packing
schemes seen in the E47-DNA complex (a bHLH protein; Ellenberger
et al., 1994) and in the USF-DNA complex (USF is a bHLH-ZIP
protein, but the crystal contains a truncated bHLH peptide with the
naturally occurring leucine zipper deleted for crystallization
purposes; Ferr6-1)'Amard et al., 1994), have DNA duplexes which
stack end on end to form pseudocontinuous helices. Even within the
context of a few bHLH and bHLH-ZIP structures then, we see a
variety of different packing schemes. Thus, with a limited ability
to predict packing a priori, the crystal grower must rely on testing
DNA sites of different lengths and sequences (especially at the
ends) in order to maximize the chances for obtaining diffraction
quality crystals of bHLH(/Z - DNA complexes, and by extension,
other protein-DNA complexes as well (Jordan et al., 985).
58
References
Anderson, J., Ptashne, J., and Harrison, S.C. (1 984). Cocrystals of
the DNA-binding domain of phage 434 repressor and a synthetic
phage 434 operator. Proc. Nati. Acad. Sci. USA 81, 1307-131 .
Anthony-Cahill, S.J., Benfield, P.A., Fairman, R., Wasserman, Z.R.,
Brenner, S.L., Stafford, W.F., 111, Altenbach, C., Hubbell, W.L., and
DeGrado, W.F. (1 992). Molecular characterization of helix-loop-
helix peptides. Science 255, 979-983.
Blackwell, T.K., and Weintraub, H (1 990). Differences and
similarities in DNA-binding preferences of MyoD and E2A protein
complexes revealed by binding site selection. Science 250, 1104-
1110.
Brennan, R.G., Roderick, S.L., Takeda, Y., and Matthews, B.W. (1 990).
Protein-DNA conformational changes in the crystal structure of a
lambda cro-operator complex. Proc. Natl- Acad. Sci. USA 87 8165-
8169.
Chakrabartty, A., Schellman, J.A., and Baldwin, R.L. (I 991). Large
differences in the helix propensities of alanine and glycine. Nature
351, 586-588.
59
Davis, R.L., Cheng, P.-F., Lassar, A.B., and Weintraub, H. (1 990). The
MyoD DNA binding domain contains a recognition code for muscle-
specific gene activation. Cell 60, 733-746.
DiGabrielle, A.D., Sanderson, M.R., and Steitz, T.A. (1 989). Crystal
lattice packing is important in determining the bend of a DNA
dodecamer containing an adenine tract. Proc. NatL Acad. Sci. USA
86,1816-1820.
Ellenberger, T., Fass, D., Arnaud, M., and Harrison, S.C. (1 994).
Crystal structure of transcription factor E47: E-box recognition by
a basic region helix-loop-helix dirner. Genes Dev. In press.
Ferrd-D'Amar6, A.R., Pognonec, P., Roeder, R.G., and Burley, S.K.
O 994). Structure and function of the b/HLH/Z domain of USF.
EMBO J. 13,180-189.
Ferrd-D'Amard, A.R., Prendergast, G.C., Ziff, E.B., and Burley, S.K.
(1 993). Recognition by Max of its cognate DNA through a dimeric
b/HLH/Z domain. Nature 363, 38-45.
Fisher, D.E., Parent, L.A., and Sharp, P.A. (1 993). High affinity DNA-
binding myc analogs: recognition by an alpha-helix. Cell 72, 467-
476.
Joachimiak, A., and Sigler, P.B. (I 99 1 ). Crystallization of protein-
DNA complexes. Methods in Enzymology 208, 82-99.
60
Joachimiak, A., Marmorstein, R.Q., Schevitz, R.W., Mandecki, W., Fox,
J.L., and Sigler, P.B. (1 987). Crystals of the trp repressor-operator
complex suitable for X-ray diffraction analysis. J. Biol. Chem. 262,
4917-4921.
1
Jordan, S.R., and Pabo, C.O. (1 988). Structure of the lambda complex
at 25 A resolution: Details of the repressor-operator interactions.
Science 242, 893-899.
Jordan, S.R., Whitcombe, T.V., Berg, J.M., and Pabo, C.O. (1 985).
Systematic variation in DNA length yields highly ordered repressor-
operator cocrystals. Science 230, 1383-1385.
Kissinger, C.R., Liu, B., Martin-Blanco, E., Kornberg, T.B., and Pabo,
C.O. (1 990). Crystal structure of an engrailed homeodomain-DNA
complex at 28 A resolution: A framework for understanding
homeodomain-DNA interactions. Cell 63, 579-590.
Kudritskaya, Z.G., and Danilov, V.I. (I 976). Quantum mechanical
study of bases interactions in various associates in atomic dipole
approximation. J. Theor. Biol. 59, 303-318.
Liu, B., Kissinger, C.R., and Pabo, C.O. (I 990). Crystallization and
preliminary X-ray diffraction studies of the engrailed homeodomain
and of an engrailed homeodomain/DNA complex. Biochemical and
Biophysical Research Communications 171, 257-259.
61
Lorber, B., and Gieg6, R. (1 992). Preparation and handling of
biological macromolecules for crystallization. In Crystallization of
Nucleic Acids and Proteins, A Ducruix and R Gieg6, eds. (New York,
New York: Oxford University Press), pp. 19-42.
Luisi, B.F., Xu, WX, Otwinowski, Z., Freedman, L.P., Yamamoto, KR.,
and Sigler, P.B. (1 991 ). Crystallographic analysis of the
interaction of the glucocorticoid receptor with DNA. Nature 352,
497-505.
McLeod, M., Stein, M., and Beach, D. (1 987). The product of the mei3+
gene, expressed under control of the mating-type locus, induces
meiosis and sporulation in fission yeast. EMBO J. 6 729-736.
McPherson, A. (1 982). Preparation and Analysis of Protein Crystals
(Malabar, Florida: Krieger Publishing Company).
Murre, C., McCaw, P.S., and Baltimore, D. (1 989). A new DNA binding
and dimerization motif in immunoglobulin enhancer binding,
daughterless, MyoD, and myc proteins. Cell 56, 777-783.
O'Neil, K.T., Hoess, R.H., and DeGrado, W.F. (1 990). Design of DNA
binding peptides based on the leucine zipper motif. Science 249,
774-778.
62
O'Neil, K.T., Shuman, J.D., Ampe, C., and DeGrado, W.F. (1 991). DNA-
induced increase in the alpha-helical content of C/EBP and GCN4.
Biochemistry 30, 9030-9034.
Ornstein, R.L., Rein, R., Breen, D.L., and MacElroy, R.D. (1 978) An
optimized potential function for the calculation of nucleic acid
interaction energies. 1. Base stacking. Biopolymers 7, 2341-2360.
Otwinowski, Z., Schevitz, R.W., Zhang, R.G., Lawson, C.L., Joachimiak,
A., Marmorstein, R.Q., Luisi, B.F., and Sigler, P.B. (1 988). Crystal
structure of trp repressor/operator complex at atomic resolution.
Nature 335, 321-329.
Patel, L., Abate, C., and Curran, T. (1 990). Altered protein
conformation on DNA binding by fos and jun. Nature 347, 572-574.
Pavletich, N.P., and Pabo, C.O. (1 991). Zinc finger-DNA recognition:
crystal structure of a Zif268-DNA complex at 21 A. Science 252,
809-817.
Saenger, W. (1 984). Principles of Nucleic Acid Structure (New York,
New York: Springer-Verlag).
Schultz, S.C., Shields, G.C., and Steitz, T.A. (1 990). Crystallization
of Escherichia co# catabolite gene activator protein with its DNA
binding site: The use of modular DNA. J. Mol. Biol 23, 159-166.
63
Starovasnik, M.A., Blackwell, TK., Laue, T.M., Weintraub, H., and
Klevit, R.E. (1 992). Folding topology of the disulfide-bonded dirneric
DNA-binding domain of the myogenic determination factor Myol).
Biochemistry 31, 9891-9903.
Studier, F.W. (1 991). Use of bacteriophage T7 lysozyme to improve
an inducible T7 expression system. J. Mol. Biol. 279, 37-44.
Tapscott, SJ, Davis, R.L., Thayer, M.J., Cheng, P.-F., Weintraub, H.,
and Lassar, A.B. (1 988). MyoD1 a nuclear phosphoprotein requiring a
myc homology region to convert fibroblasts to myoblasts. Science
242, 405-411.
Van der Laan, J.M., Swarte, M.B.A., Groendijk, H., Hol, W.G.J., and
Drenth, J. (1 989). The influence of purification and protein
heterogeneity on the crystallization of p-hydroxybenzoate
hydroxylase. Eur. J. Biochem. 79, 715-724.
Weiss, M.A., Ellenberger, T.E., Wobbe, C.R., Lee, J.P. Harrison, S.C.,
and Struhl, K. (1 990). Folding transition in the DNA-binding domain
of GCN4 on specific DNA binding. Nature 347, 575-578.
Wolberger, C., and Harrison, S.C. (1 987). Crystallization and X-ray
diffraction studies of a 434 cro-DNA complex. J. Mol. Biol. 196,
951-954.
64
Wolberger, C., Pabo, C.O., Vershon, A.K., and Johnson, A.D. (1 991 a.
Crystallization and preliminary X-ray diffraction studies of.a
MATa2-DNA complex. J. Mol. Biol. 217,11-13.
Wolberger, C., Vershon, A.K., Liu, B., Johnson, A.D., and Pabo, C.O.
(11 991 b). Crystal structure of a MATa 2 homeodomain-operator
complex suggests a general model for homeodomain-DNA
interactions. Cell 67, 517-528.
Zeppenzauer, M. (1 971 ). Formation of large crystals. Methods in
Enzymology 22, 253-266.
Table Leaends
Table 1: DNA sequences used in cocrystallization
experiments with Myol).
We summarize the results of cocrystallization experiments
between various Myol) peptides and the DNA oligorners shown in this
table. For each of the oligomers shown, we have highlighted in bold
the E-box bases: CAGCTG , CAGGTG, or CACCTG. The column
labeled "Diffraction" refers to the diffraction limit of the crystal
tested.
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FigUre eagnd
Figure 1: Expression plasmid pRK1 71 a.
Schemaic of the expression plasmid (provided by Harold Weintraub)
used for the overexpression of the MyoD bHLH peptides.
Figure 2 Primary sequence of MyoD peptides tested in
crystallization studies.
Sequence alignment of the peptides (produced from cDNA clones
provided by Harold Weintraub) used in our cocrystallization trials.
Amino acid residues are given in one-letter code.
Figure 3 Capillary zone electrophoresis on MyoD.
Analysis of the MD-bHLHC1 35S peptide shows that the peptide
runs as a single peak. (Analysis performed with the help of
Jonathan Weissman, M.13).
Figure 4 CD difference spectroscopy in the presence of
DNA.
CD absorption spectrum for 5.5 yM of MyoD (open squares), 5 pM of
DNA (closed squares), and the difference spectrum obtained from
subtracting the DNA component of .5 pM Myol) plus .5 pM DNA
(closed diamonds).
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Figure 5: CD absorption spectroscopy of Myol) in the
absence and presence of DNA.
The figure is similar to that of Figure 4 For clarity, we don't show
the absorption spectrum for DNA. The ordinate of the graph is
measured in units of molar ellipticity (in units of deg*CM2/dmol).
Figure 6 Asymmetric DNA oigorners can form part of a
symmetric repeating unit.
Schematic showing how the symmetric two base-pair overhangs of
an asymmetric DNA oligomer can lead, through the base pairing of
the overhangs, to symmetric repeating units.
Figure 7 Asymmetric unit of the MyoD/DNA cocrystals.
The asymmetric unit of the MyoD/DNA cocrystals contain two
copies of a dimer of MyoD bound to a 4bp DNA site (see Chapters 3
and 4 for details on structure determination). The DNA sites are
shown in gold and red. The alpha carbon traces from each one of the
four MyoD peptides (from the two dimers) are shown in a different
color: white, green, pink, and blue.
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Figure 8: Crystal packing contacts in the unit cell of the
MyoD/DNA cocrystals.
Figure 8a shows the unit cell, in which the view is of the plane
formed by the a and b unit cell edges. We show the arrangement of
the DNA within the unit cell, leaving out the protein molecules for
now. Notice that the DNA oligomers are grouped by two, since each
asymmetric unit contains two copies of a 14 bp DNA oligomer.
Also, the DNA oligomers do not stack end on end to form a pseudo-
continuous helix through the unit cell. The view in Figure 8 is
rotated 900 along the axis following the a unit cell edge. Thus, the
view is of the plane formed by the a and c unit cell edges. As in
Figure 8a, we show only the DNA oligorners. Figure 8c shows an
identical view to that in Figure 8a, except now, both the protein and
the DNA molecules within the unit cell are shown. Notice that there
are numerous protein-protein, and protein-DNA contacts between
members of different asymmetric units within this unit cell.
Figure 9 Crystal packing contacts between molecules
belonging to two adjacent asymmetric units.
We show the contents of two adjoining asymmetric units. The two
MyoD dimer/DNA complexes in the center of the unit cell are from
different asymmetric units. Notice the protein-DNA contacts
between helix 2 and the loop regions of the MyoD dimers and the
terminal base pairs of the DNA.
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MD-bHLH
MELKRKTTNADRRKAATMRERRRLSKVNEAFETLKRCTSSNPNQRLPKVEILRNAIRYIEGLQALLRD
MD-bHLH C135Y
MELKRKTTNADRRKAATMRERRRLSKVNEAFETLKRYTSSNPNQRLPKVEILRNAIRYIEGLQALLRD
MD-bHLH C135Y
NELKRKTTNADRRKAATMRERRRLSKVNEAFETLKRSTSSNPNQRLPKVEILRNAIRYIEGLQALLRD
sMD-BHLH C135Y
MADRRKAATMRERRRLSKVNEAFETLKRYTSSNPNQRLPKVEILRNAIRYIEGLQALLRD
sMD-BHLH C135S
MADRRKAATMRERRRLSKVNEAFETLKRSTSSNPNQRLPKVEILRNAIRYIEGLQALLRD
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MyoD 0.8 mg/ml
CZE pH 20 30*C 821/92
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The following oligomers are asymmetric:
M21-5 ATCGCAALAGCTGTTGGACTA 51
31 GCGTTGTCGACAACCTGATGC 31
M21-6 51 ATGCAACAGCTGTTGGTACTA 51
31 CGTTGTCGACAACCATGATGC 31
M21-7 5' ATCGACAACAGCTGrTGGCTA 51
31 GCTGTTGTCGAC.ACCTGTGC 31
M20-5 51 ATCGCAACAGCTGTTGGACT 51
31 GCGTT(;TCGACAACCTGAGC 31
M22-2 51 ATCGGCAACAGCTGTTGGTACT 51
31 GCGGTTGTCGACAACCATGAGC 31
BUT they can f orm a part of a
symmetric repeating unit
For example:
M21-5 ..
ATCGCAACAGCTGTTGGA GTCCAACAGCTGTTGCG
GCGTTGTCGACAACCT CAGGTTGTCGACAACGCTA
M21-5
M21-6
ATGCAACAGCTGTTGGTA GTACCAACAGCTGTTCG
CGTTGTCGACAACCAT CATGGTTGTCGACAAGCTA
M21-6
M21-5
ATCGACAACAGCTGTTGGCTA-b',."i."..'-'-"'.-"TAGCCAACAGCTGTTGTCG
GCTGTTGTCGACAACCGA-.G.. TCGGTTGTCGACAACAGCTA
M21-5
Figure 6
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CHAPTER 3
Details of the Structure Determination
84
of the MyoD bHLH-DNA Complex
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jAs described in the previous chapter, by using the DNA site
Ml 412, we were able to grow cocrystals with MyoD that diffracted
to 26 A resolution. Our general approach to structure
determination relied on using modified DNA in our cocrystals to
produce substitutions for solving the phase problem. Specifically,
we synthesized DNA oligomers in which 5-iodouracil and/or -
iodocytosine were introduced as substitutions for thymine and
cytosine respectively (Anderson et al., 1987; Wolberger et al., 988;
Jordan and Pabo, 1988; Aggarwal et al., 1988). We tested a number
of these modified DNA oligomers in cocrystallization trials, and
found that two of these oligomers produced crystals which were
useful for phasing. Model building of the protein-DNA complex was
done with the computer graphics program FRODO (Jones, 1978) and
refinement of the model used the programs XPLOR (Brunger et al.,
1987; Brunger, 1992) and TNT (Tronrud et al., 1987). This chapter
summarizes our results and methods from the structure
determination, focusing on areas that were not discussed in detail
in the 'Experimental Procedures' section of Chapter 4 (which
concentrates on describing and analyzing the structure of the
complex). After discussing the preparation of heavy atom
derivatives using DNA oligomers with halogenated substitutions, we
discuss our data collection and data reduction strategies. The
unusual shape of the unit cell (a = 222.8 A, b = 70.8 A, c = 30.0 A)
required extra care in the data collection and data reduction. A
discussion of the phasing procedures, in which we used heavy atom
parameter refinement and solvent flattening techniques, is next,
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followed by some comments on our model building. A brief
discussion of the refinement procedures ends this chapter.
A. Preparation of Heavy Atom Derivatives
We tested a number of different DNA sites in which thymine
and/or cytosine bases were substituted by pyrimidines with iodine
at the position (Table 1. With the two-fold symmetry in our DNA,
we expected that the DNA would be symmetrically substituted. The
two DNA duplexes which gave crystals suitable for phasing, 1 1 +1 1'
and 12+12', each contained two iodines. We tested a total of nine
substituted oligorners in cocrystallization trials under conditions
identical to those which gave native cocrystals. Five of the
oligomers tested produced crystals. Of the four oligomers which
did not produce crystals, three of these were substituted at bases
inside the core 6 bp CAGCTG region and thus, might have interfered
with DNA binding by the MyoD peptide; the fourth oligomer was
substituted at the S' base position, which could have affected how
the DNA stacked against other DNAs and/or Myol) peptides. For the
crystallization trials, as well as for the synthesis and purification
steps, we were careful to limit the exposure of the iodinated DNA
to UV and visible light, working in the dark whenever possible
and/or using aluminum foil to cover photochernically sensitive
reagents. In addition to guarding against photochemical reactions
of the iodine, we were careful not to overreact the iodine-
substituted oligonucleotides with ammonia during the base
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deprotection steps, or with tricholoracetic acid during the
detritylation steps.
We found that the iodine-substitutions were quite sensitive
to exposure to ammonia during the base deprotection steps. Our
initial derivative crystal ( 212', first crystal) did not give an
easily interpretable difference Patterson map (viewed by Harker
sections). We suspected that the iodine-substituted DNA used in
this derivative crystal may have been damaged during synthesis
and/or purification. Earlier conversations with Stephen Burley
(Rockefeller University) had suggested that iodine-substituted DNA
may be especially sensitive to ammonia treatment during the base
deprotection steps; he also suggested to us that we try ion-
exchange chromatography for purification of the DNA since this was
a standard practice in his laboratory (personal communication). We
decided to test if ion-exchange chromatography could be used to
detect impurities in our iodine-substituted DNA. Figure shows a
chromatograph from the trityl-off reverse-phase HPLC step in our
purification of the DNA with iodine substitutions at positions
12+12'. The trityl-off chromatography step is normally the final
step in our purification procedure for synthetic oligonucleotides
(see Chapter 2. The chromatograph in Figure shows a single
dominating peak with a slight shoulder at the front end of the peak.
Before we had discussed the problems of purifying iodinated DNA
oligonucleotides with Stephen Burley, we had hoped that a
conservative collection of the peak shown in Figure would result
in a relatively pure product; we used this DNA to grow our initial
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derivative crystal. After we grew these initial derivative crystals
and had discussions with Stephen Burley, we retested the purity of
our iodine-substituted oligomers by running them through an ion-
exchange column. We used a Mono Q anion exchange column
(Pharmacia LKB, Piscataway, New Jersey) with running buffer
containing 1 0 mM NaOH, pH 2 Column elution was done by means
of a gradient of 200 mM to 1 000 mM NaCl. Figure 2b shows a
chromatograph of what we had thought was purified DNA oligomer
with iodines at 12+12'. The chromatograph shows that there was a
significant impurity in our substituted DNA. An ion-exchange run of
purified DNA without iodine substitutions (Ml 412) suggested that
the impurity was probably due to some modification of the iodines
during synthesis and/or purification (compare Figure 2a with Figure
2b). When we mixed the unsubstituted Ml 4-12 DNA together with
the substituted 12+12' DNA and ran the mixture on the ion-exchange
column, we saw that the impurities in Figure 2b and 2c seemed to
elute at around the same point in the chromatograph as the
unsubstituted DNA did (Figures 2a, 2b, and 2c), which also
suggested that the iodines in the substituted DNA had been modified
during synthesis and/or purification.
At this point, we reviewed our DNA synthesis and purification
protocols to look for steps where damage to the iodinated
substitutions might occur. After DNA synthesis, our normal
procedure was to remove the alkaline-labile base-protecting groups
by treating them with a saturated ammonia solution for to 5
hours at 550; this procedure followed that recommended by the
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manufacturers of the phosphoramidites (Applied Biosystems, Foster
City, CA). Given the problem of impurities with the iodine-
substituted oligos, we decided to test the effects of using fast
oligonucleotide deprotecting (FOD) phosphoramidites (Applied
Biosystems, Foster City, CA) for the synthesis of the iodine-
substituted DNA. FOD phosphoramidites use a different protecting
group than the standard phosphoramidites: dimethylformaminidine
and isobutyryl groups for FDs vs. benzoyl and isobutyryl groups for
standard phosphoramidites. The result of using different base-
protecting groups is that FDs can be deprotected by treatment
with saturated ammonia at 5 50 for only hour versus - hours
for the standard chemistry. We suspected that the reduced exposure
to saturated ammonia with DNA oligomers synthesized with FOD
phosphoramidites might limit damage to the iodine-substitutions.
To test this, we synthesized iodine-substituted oligomers using the
FOD phosphoramidites. We purified these oligomers according to
our usual protocol and then ran the purified products on the ion-
exchange column. The chromatograph showed that using the FOD
phosphoramidites and limiting the exposure of the oligomer to
saturated ammonia during base deprotection significantly decreased
the amount of impurity in the iodine-substituted oligomers (Figure
2d). Thus, from that point on, we always used FOD
phosphoramidites for the synthesis of iodine-substituted oligomers
and were careful to test samples of our oligomers for impurities
using ion-exchange chromatography. With these additional
procedures, we felt that it was not necessary to include an
additional purification step of ion-exchange chromatography after
the two reverse-phase HPLC purification steps. We also decided at
this point that given the subtle differences in impurity that could
arise in iodine-substituted oligomers during synthesis and
purification, we would treat all derivative crystals independently
during data collection and reduction.
B. Data Collection and Reduction
Mounting of Crystals and Initial Anal,
The best Myol) cocrystals grew out of 10-1 5% PEG 4000, 1 00
mM Tris, pH 8.5, 1 00 mM NaCitrate, 20 mM BaC12 at room
temperature. The largest crystals measured 03 mm x 03 mm x 04
mm, and in spite of having well-defined faces and edges, were not
homogenous in morphology. The crystals were very sensitive to
changes in solvent content. During mounting, we found that adding
any type of buffer or solution, including well buffer, to the hanging
drop produced cracks in the crystals. Thus, we mounted the
crystals directly out of the hanging drops using thin-walled glass
capillary tubes of 1.0 mm or 07 mm diameter (Charles Supper
Company, Natick, MA). After mounting, crystals were examined for
their diffraction characteristics by taking still 'photographs' on a
Rigaku RAXIS-IIC imaging plate area detector.
The crystals have unit cell dimensions of a = 222.8 A, b = 70.8
A, c = 30.0 A, and are of the orthorhombic space group P21212.
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Initial determination of the lattice parameters was done by first
collecting three 1 O' wedges of data (in the phi direction; Aphi = 1')
with each 1 O' wedge separated by at least 300 in phi. After
collecting the wedges of data, the positions of the individual spots
on the oscillation photographs were converted to positions in
reciprocal space using conversion programs developed by Mark Rould
(extract-peaks.for, peaks-to-reciprocal-space-coordinates.for,
M. Rould). We then measured the distances and angular separation of
the individual spots in reciprocal space with the aid of the
computer graphics program FRODO (Jones, 1978) and this allowed us
to directly determine the reciprocal lattice parameters. We
inferred from the spot pattern and the fact that all angles were
very close to 900 that we had a primitive orthorhombic space group;
we confirmed this by testing for the presence of the two-fold
symmetry operators. The identification of the two two-fold screw
axes was made only after a native data set was collected and
examined for systematic absences; solution of the difference
Patterson function allowed us to definitively identify the space
group as P21212.
We used the lattice parameters to help estimate the
stoichiometric contents of the asymmetric unit of the crystal along
with the solvent content. If we assume that there are two copies of
a MyoD dimer bound to a 14 bp DNA site in each asymmetric unit, we
get a of 239 A3/dalton and a corresponding solvent content of
55%. The value for is within the range of 16 A3 Da- to
3.5 A3 Da-1 found for most protein crystals (Matthews, 968).
2. Data Colleclion Strat OV
With the oscillation method of data collection, there are a
few important considerations in choosing the orientation of the
crystal axes and angular range of phi and Aphi 1 completeness of
the data in the minimum number of frames; 2 adequate redundancy
for internal scaling; 3 absorption and 4 convenience in crystal
mounting (Wonacott, 1977; Harrison et al., 1985). The unusual
shape of the MyoD cocrystal's unit cell, with its very long a axis
(222.8 A), and short c axis 30.0 A), suggested that the crystals
should be mounted with the a axis aligned parallel to the spindle
axis so as to minimize spot overlap. Unfortunately, we found that
the features of the crystals (i.e. faces and edges) did not have a
reproducible correspondence with the axes of the unit cell. Thus, it
was difficult for us to determine the orientation of the crystal axes
from the crystal morphology alone. If after taking still
photographs, we determined that a crystal was mounted such that
the a axis was aligned perpendicular to the spindle axis, we could
not realign the crystal in a position more favorable for efficient
data collection without remounting the crystal (our area detector
system only has a single axis of rotation, phi). As the MyoD
cocrystals were quite fragile, they usually did not survive
remounting without significant damage. Thus, for crystals aligned
such that the a axis was perpendicular to the spindle axis, we
minimized spot overlap during data collection by using Aphi's of
only 0.5'. Wonacott gives the following formula as a guide to
choosing the maximum Aphi which will avoid overlapping reflexions
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for an orthorhombic cell with the a* axis along the X-ray beam
when 0 (Wonacott, 977):
AO = Qia) r/X) (1 80/ic) - A
where a = 222.8 A, r = maximum resolution = 26 A, A = minimum
rocking range of the crystals.
The MyoD cocrystals have values of A somewhere between 03
and 04. Given this value for A, Wonacott's formula suggests that
our maximum Aphi is between 027' and 037'. Thus, using a A phi of
0.5' would likely result in a number of overlapping reflexions in the
higher resolution shells which would have to be discarded during
measurement. We chose a lower limit for Aphi of 0.5' because the
DENZO software (Z. Otwinowski) we used to reduce the data required
a minimum number of fully recorded ref lexions in order to process
the data effectively. A smaller value than 0.50 for Aphi would
result in too many partially recorded reflections.
3. Data ReductiQn
We used the program DENZO (Z. Otwinoski) for our data
reduction. Crystal and camera parameters were refined, and
intensity measurements were made by using profile fitting of the
recorded spots. We handled partially recorded reflexions by
merging successive oscillation frames and integrating the spot
intensities over the merged oscillation frames (merge-denzo.for,
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M. Rould). Data were scaled using the program SCALEPACK (Z.
Otwinowski) after dividing the merged oscillation frames divide-
merged-denzo.for, M. Rould). We applied a single scale factor for
each ' wedge of data. No explicit corrections were made for
absorption or crystal decay. For each of our two native data sets,
we combined the data from two separate crystals. Given our
concerns about variations in impurity in the iodine-substituted
DNA, we treated each derivative crystal individually (attempts to
merge data from two different crystals for the 12+12' derivative
resulted in high values for RsYM9 reinforcing our decision to treat
each derivative crystal individually). Tables 2 through 7 show final
outputs from the SCALEPACK program which summarize the data
redundancy, Rsym values, and intensities for each resolution shell of
the data sets. In order to reduce systematic errors in our
derivative data sets, we used the program DSCALE-AD (M. Rould to
local-scale each derivative data set to the native data set
(Matthews and Czerwinski, 975). The locally-scaled derivative
data was used in the calculation of Cross R-values (see Table ,
Chapter 4, and all subsequent phasing procedures.
4. Phasina -Model Buildina and Refinement
Isomorphous difference Patterson and anomalous difference
Patterson maps (Figures 3 4 and 5) were calculated for each
derivative crystal using the program PROTEIN (Steigemann, 1 974).
Figure 3 shows the Harker sections from a representative
isomorphous difference Patterson map calculated from native data
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and a 21 2 derivative (second crystal) dataset. The periodicity of
peaks in the Harker sections show that a few terms bias the map.
After removing the reflexions with large intensity differences (>7a)
between the native and derivative data sets 6 reflexions), we used
local-scaling again on the derivative data set, and then calculated
new difference Patterson maps. Figure 4a shows that removing the
reflexions with the large intensity differences significantly
improved the interpretability of the maps as viewed from the
Harker sections; we treated all subsequent Patterson maps for the
other derivatives in a similar manner. Even with this map
improvement, however, it was not straightforward to identify all of
the heavy atom sites from the Harker sections alone. From our
calculations of solvent content, we expected that we would have
two copies of a MyoD dirner bound to DNA in each asymmetric unit.
Given that the 2+1 2 derivative was doubly substituted with
iodine, we expected a total of four heavy atom sites in each
asymmetric unit. Using the Harker sections as a guide, we picked
potential heavy atom sites. We used the program HASSP \ et al.,
1987) as an independent method to pick potential heavy atom
positions. HASSP works by systematically searching the difference
Patterson function for heavy atom sites which have large values for
both the self- and cross-vector positions. In the case of the second
crystal for the 12+12' derivative, HASSP picked out four potential
sites. These sites were also found in our Harker sections of the
isomorphous difference Patterson map. There were also
corresponding peaks in the anomalous difference Patterson maps for
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this derivative, but these peaks were not as clear as in the
isomorphous difference Patterson maps (Figure 5a).
For the other derivative crystals, we used similar procedures
to the one described above for identifying the positions of the heavy
atom sites (Figures 4 and 5). Once we had identified candidate
sites for the heavy atoms by using the results from HASSP and the
difference Patterson maps, we refined the heavy atom parameters
for the derivative crystal against the centric reflexions using the
program REFINE from the CCP4 package (S.E.R.C, 1979). After
refining the heavy atom parameters (occupancy, position, and
thermal parameter) for the 1 1 + 1 1 , and 2 2 derivatives, we used
the refined positions of the heavy atom sites to fix the origin of the
unit cell with respect to the positions of the heavy atom sites from
the two derivatives. Since the 1 1 +1 V, and 12+12' derivatives have
iodine substitutions on adjacent bases, we expected that the
positions of the heavy atom sites from the two derivatives should
differ by between 35 to 45 A for each site. We used these
expected differences in positions to fix the origin of the unit cell.
With the major heavy atom sites identified and initially refined for
each derivative, we used difference Fourier methods to check the
correctness of the heavy atom sites and to identify any additional
sites. For the 1 1 +1 1' derivative (first crystal), we had originally
identified and refined three heavy atom sites. Using these three
sites, we calculated a difference map for the residuals (Henderson
and Moffat, 1971) and were able to identify a fourth heavy atom
site. Thus, both the 21 2 and 1 1 + 1 1 derivatives contained four
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heavy atom sites, as expected. The final heavy atom parameters
from REFINE for each derivative are shown in Table .
After refining the heavy atom parameters for each derivative
crystal individually with REFINE, we used the program PHARE
(S.E.R.C., 979) for phase-refinement using data from all of the
derivative crystals. Since we had data sets from four derivative
crystals (two crystals each of derivatives 1 1 +1 1' and 21 2) we
used cross-phased refinement in order to reduce bias (Blow and
Matthews, 973). With this procedure, the parameters of one
derivative are refined while the other derivatives are used to
calculate phases. After each derivative was refined twice by
cross-phased refinement (8 rounds of refinement in total; see Table
9), we generated an initial M.I.R. map. At this stage, the map was of
reasonable quality; we were able to identify alpha-helical regions,
as well as much of the phosphate backbone of the DNA. In order to
improve the quality of our phases, we used a procedure developed by
Mark Rould (Rould et al., 992). The procedure decouples heavy atom
parameter refinement from the calculation of parent phases by first
solvent flattening (Wang, 985) the initial M.I.R. map in order to
generate new solvent-flattened phases. These new phases, in turn,
are used in the re-refinement of the heavy atom parameters; during
this re-refinement, the phases are not updated. After convergence
of the refinement, new M.I.R. phases are calculated and the
procedure is repeated, if desired. The parameters from this heavy-
atom refinement against solvent-flattened phases are shown in
Table 1 0. This additional refinement step improved the figure of
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merit from 03 to 065, and more importantly, improved the
interpretability of the M.I.R. map.
Using this solvent-flattened M.I.R. map, we modeled the alpha-
helical regions as polyalanine helices and the loop region as an
extended polypeptide chain. We placed idealized B-form DNA
(generated by INSIGHT) in the density and then adjusted each
nucleotide to improve the fit. After completing this initial model,
we used the program (Jones et al., 991 to superimpose each
monomer of MyoD and half of each DNA duplex on a reference MyoD
monomer and DNA half-site. We used the rotation and translation
matrices generated by this superposition to find the non-
crystallographic symmetry axes within the asymmetric unit. By
using the non-crystallographic symmetry axes to superpose parts of
the M.I.R. map (each part corresponding to an individual monomer and
DNA half-site) on a region of the M.I.R. map corresponding to a
reference MyoD monomer and DNA half-site, we generated a four-
fold non-crystallographic symmetry averaged M.I.R. map. We note
that after generating this map, we did not use iterative real-space
averaging (Bricogne et al., 1976) to improve the quality of the maps
since we felt that the non-crystallographic symmetry averaged
M.I.R. map (which had also undergone heavy atom refinement against
solvent-flattened phases) was already of high quality. The main
chains of the alpha-helices and the loops were visible, as were
most of the side chains. The DNA was also well-resolved, with
clear density for both the phosphate backbone and the base pairs.
Model building was done primarily with the program FRODO (Jones,
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1978) written for use on the Evans and Sutherland's PS390. A more
recent version of FRODO, written for Silicon Graphics machines,
contains a data base of protein structures from which the modeler
can fit fragments of a protein chain to the electron density (Jones
and Thirup, 986). We found the use of this DGLP feature to be very
useful in building the loop regions of our model. Figure 6 shows
various parts of our model with the corresponding M.I.R. density. We
refined our model using the programs XPLOR (Brunger, 1987, 1992)
and TNT (Tronrud, 1987), monitoring the course of our refinement
with the Rfreeand R values (See 'Experimental Procedures' section
of Chapter 4 for detailed discussion about refinement). Figure 7
shows a Ramachandran plot for the final refined structure. The
Ramachandran plot shows that only one residue (out of 248) is in a
region that is not favorable (Morris et al., 1992). This residue, Asn
343, is in one of the four loops in our asymmetric unit (we have two
bHLH dimers per asymmetric unit) and is in a region where the exact
structure of the chain is more difficult to determine.
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Table Leaends
Table 1: Iodine-substituted DNA sites.
Sequences of DNA oigonucleotides which had thymine bases
replaced by 5-iodouracil and/or cytosine bases replaced by
5-kxiocytosine. We summarize the results of cocrystallization
trials with these DNA oligomers and MyoD peptide MD-bHLHC1 35S
(see Figure 2 Chapter 2 for primary sequence of this peptide). The
column "Diffraction" refers to the diffraction limit of the crystal
tested.
Table 2 Summary of data reduction statistics for Native
Data Set .
We show the summary of output from the program SCALEPACK (Z.
Otwinowski), which was used for the scaling of the diffraction data
(redtxed with the program DENZO (Z. Otwinowski) ). This native
data set contains the merged data from two separate native
crystals.
Table 3 Summary of data reduction statistics for Native
Data Set 2.
This native data set contains the merged data from two separate
crystals. These two crystals diffracted to a higher resolution 2.6
A versus 28 A) than the two native crystals used for Native Data
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Set Attempts to merge Native Data Set with Native Data Set 2
resulted in higher values for Rsym than the values for the individual
native data sets (Rsym = .1 % for the merged Native Data Set plus
Native Data Set 2 Rsym = 79 % for Native Data Set 1; Rsym = 65%
for Native Data Set 2; thus, we have kept the two native data sets
separate. The higher RYM value that resulted from merging the two
native data sets could have been due in part to the fact that the two
crystals used in Native Data Set had a different crystal alignment
(a axis parallel to the spindle axis) than the crystal alignment for
the two crystals used in Native Data Set 2 (a axis perpendicular to
the spindle axis).
Table 4 Summary of data reduction statistics for 12+12'
derivative (First crystal).
The data is from a cocrystal containing DNA which had thymine
replaced by 5-iodouracil at the 12 and 12' positions (for numbering
scheme, see Table 1. As explained in the text, we treated data
from each derivative crystals separately. Thus, this data set is
from one derivative crystal only.
Table 5: Summary of data reduction statistics for 12+12'
derivative (Second crystal).
The data is from a single derivative crystal.
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Table 6 Summary of data reduction statistics for 1 1 +1 1'
derivative (First crystal).
The data is from a cocrystal containing DNA which had thymine
replaced by 5-iodouracil at the 1 1 and 1 1' positions. The data is
from a single derivative crystal.
Table 7 Summary of data reduction statistics for 1 1 +1 1'
derivative (Second crystal).
The data is from a single derivative crystal.
Table 8: Heavy atom parameters after refinement on
centric reflexions from each individual derivative crystal.
The heavy atom parameters (an overall scale factor for each
crystal, and the occupancy, isotropic temperature factor (B factor),
and coordinates for each iodine site) from each individual
derivative crystal were refined separately against centric
reflexions using the program REFINE from the CCP4 package
(S.E.R.C., 979). The heavy atom parameters shown are from after
two rounds of refinement with REFINE.
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Table 9 Heavy atom parameters after cross-phased
refinement.
Heavy atom parameters (an overall scale factor for each crystal, an
overall isotropic temperature factor (B factor) for each crystal, and
the real occupancy, anomalous occupancy, isotropic temperature
factor, and coordinates for each iodine site) from all of the
derivative crystals were refined using cross-phased refinement
(see text for details) with the program PHARE from the CCP4
pac kage (S.E.R.C., 1979). The heavy atom parameters shown are
from after two rounds of refinement with PHARE.
Table 1 0: Heavy Atom Parameters after cross-phased
refinement against solvent-flattened phases.
The procedure follows that first presented in Rould et al., 1992, and
is discussed further in the text. The heavy atom parameters are
from after one round of refinement with PHARE.
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Figure 1: Reverse-phase HPLC chromatography on iodine-
substituted DNA.
We show a chromatograph from a trityl-off reverse-phase HPLC run
on DNA which had 5-iodouracil substituted for thymine at the 2
and 12' positions (see Chapter 2 for further discussion of the DNA
purification protocol). The DNA elutes as a single peak with a
shoulder at the front end of the peak. The gradient is represented
by sloping lines running from right to left and is shown at the
bottom of the graph. The scale shown records the percentage of
eluant (acetonitrile in 50 mM triethyl ammonium acetate, pH 60 at
points within the eution gradient. On the DNA peak, we have
marked our cut-off points for collection of the eluting peak.
Figure 2 Ion-exchange chromatography on iodine-
substituted DNA.
DNA with 5-iodouracils substituted for thymine at the 2 and 2'
positions were purified by two rounds of reverse-phase HPLC
chromatography (the chromatograph from the final round of
reverse-phase HPLC chromatography is shown in Figure 1). After
annealing the HPLC-purified DNAs, we ran them through a Mono Q
ion-exchange column (Pharmacia LKB, Piscataway, New Jersey; see
text for details of protocol). Figure 2a shows the ion-exchange run
of DNA oligomer Ml 4-12 (the DNA used in the native crystals; it
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was purifed by reverse-phase HPLC and does not contain iodine
substitutions). The DNA elutes as a single peak. The gradient of the
chromatography run is represented by a sloping line running from
left to right. The scale shown records the percentage of eluant (1 
NaCl in IO mM NaOH, pH 12) at points within the elution gradient.
Figure 2b shows the ion-exchange run of DNA with 12+12' iodine
substitutions (purified by reverse-phase HPLQ. Notice that in
contrast to the DNA in Figure 2a, this DNA elutes as two peaks, with
the left-most peak eluting at a position in the gradient similar to
that of the Ml 412 DNA peak shown in Figure 2a. Since the left-
most peak is the smaller of the two, we assume that it is an
impurity. In Figure 2c, we had mixed the Ml 412 DNA with the
12+1 2 iodine-substituted DNA before running the mixture through
the ion-exchange column. Notice that the height of the left-most
peak is larger for the mixture than for the 21 2 iodine-
substituted DNA alone (compare Figure 2b with Figure 2c),
suggesting that the impurity in Figure 2b has similar elution
characteristics to that of the unsubstituted Ml 41 2 DNA. Figure d
shows the ion-exchange run of 12+12'-substituted DNA which had
been synthesized using FOD phosphoramidites and purified by
reverse-phase HPLC (see text for details). Notice that in contrast
to Figure 2b, the height of the left-most peak is much smaller.
Figure 3 Isomorphous difference Patterson map.
Harker sections from the 12+12' derivative (second crystal). We
show three sections of the isornorphous difference Patterson map,
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corresponding to u= 1 2, v= 1 12, and w =0, calculated from Native
Data Set and data from the 12+12' derivative (second crystal).
The map was generated by the program PROTEIN (Steigemann, 1975)
and covers data from 20 to 30 A. The contours of the maps start at
1 sigma and are in increments of sigma. Notice that the maps
show a strong periodicity of peaks. The map was thus, difficult to
interpret. Removing the terms with large intensity differences
between the native and derivative sets resulted in more
interpretable maps (Figure 4.
Figure 4 somorphous difference Patterson maps after
removal of reflexions with large intensity differences
between the native and derivative data sets.
We removed reflexions with a greater than 7 sigma difference in
intensity between the native and derivative data sets. Notice that
the maps are no longer dominated by a periodicity of peaks as in
Figure 3 Figure 4a shows Harker sections from the 2+1 2'
derivative (second crystal). Figure 4b shows Harker sections from
the 12+12' derivative (first crystal). Figure 4c shows Harker
sections from the 1 1 +1 1' derivative (first crystal). Figure d
shows Harker sections from the 1 1 +1 1' derivative (second crystal).
In the maps, peaks which correspond to the heavy atom sites of the
derivative are circled.
ill
Figure 5: Anomalous difference Patterson maps.
We show Harker sections calculated from anomalous differences for
each derivative data set. Before generating the maps, we removed
the reflexions with large intensity differences > 6 sigma) between
the primary and friedal mates of an anomalous pair. Figure a
shows Harker sections from the 12+12' derivative (second crystal).
Figure 5b shows Harker sections from the 12+1 2 derivative (first
crystal). Figure Sc shows Harker sections from 1 1 +1 1' derivative
(first crystal). Figure 5d shows Harker sections from the 1 1 +1 1'
derivative (second crystal). Notice that the peaks in the anomalous
difference Patterson maps are generally not as clear as in the
isomorphous difference Patterson maps (Figure 4 Peaks or regions
of the maps which correspond to the heavy atom sites of the
derivative are circled.
Figure 6 Electron density for the MoD/DNA structure.
M.I.R. maps were made after heavy-atom parameter refinement of
solvent-flattened phases and subsequent recalculation of the
phases. As a final step, we averaged the M.I.R. map about the two
separate non-crystallographic symmetry axes within each
asymmetric unit. This figure shows the solvent-flattened MR
electron density map at 30 A resolution after four-fold non-
crystallographic symmetry averaging. The maps are contoured at 
sigma and are superimposed on stick figures showing the final
model. a) shows the M.I.R. electron density around the DNA. b)
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shows the M.I.R. electron density around the loop region of the MyoD
peptide. Starting at the top center of the figure and moving
clockwise, we show residues 136 to 146, which has the sequence
TSSNPNQRLPK. shows the M.I.R. electron density around helices 
and 2 We show a region at the dimer interface (corresponding to
the region A discussed in Chapter 5). Helix is shown in yellow and
Helix 2 (from the other monomer within the MyoD dimer) is shown
in magenta. Starting from the bottom center of the figure and
moving upwards, we show residues 120 to 135 from helix I (which
has the sequence RRLSKVNEAFETLKRS ) and residues 146 to 1 58
from helix 2 (which has the sequence KVEILRNAIRYIE ). d) shows the
M.I.R. electron density at the carboxy terminal ends of the MyoD
pe.ptide. We show the dimer interface between helix 2 and helix 2.
Residues 152 to 166 (with the sequence NAIRYIEGLQALLRD) are
shown for each helix.
Figure 7 Ramachandran plot.
This figure shows the location in PhiPsi space of each amino acid
residue from the final model of the MyoD/DNA complex. The angle
phi (which measures the dihedral angle about the N-Ca bond) is
shown on the abscissa, and the angle psi (which measures the
dihedral angle about the Ca-C bond) is shown on the ordinate.
1) 1+1
5 CAACAGCTGTTGA 3 no crystals n/a
31 AGTTGTCGACAACU 51
2) 12+121 diffraction
51 TCAACAGCTGT.UGA 3 crystals
31 AGIITGTCGACAACT 5' ( - 28
3) 11+111 diffraction
51 TCAACAGCTGUTGA 3 crystals
31 AGTSIGTCGACAACT 5 2.8 A
4) 991
5 1TCAACAGCUGTTGA 3 no crystals n/a
31 AGTTGUCGACAACT 51
5) 11,12 111,121 diffraction
51 TCAACAGCTG=GA 3 crystals
31 AGMGTCGACAACT 5 ( -4
6) 2,12 2121 diffraction
5' T.QAACAGCTGT.UGA 3 crystals
3 AIITGTCGACAALT 5 ( 4
7) 2+21 diffraction
51 TCAACAGCTGTTGA 3 crystals 4
31 AGTTGTCGACA-ACT 51
8) 5+51
51 TCAAQAGCTGTTGA 3 no crystals n/a
31 AGTTGTCCAZAACT 5'
9) 8+81
51 TCAACACCTGTTGA 3 no crystals n/a
31 AGTTGTfGACAACT 51
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Crvstals DiffractionDerivative
.Q= 5-iodocytosine.U= 5-iodouracil
Table 1
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Nat ive 1
Shell
Lower Upperlimit limit
20-00 5.76
5.76 4.59
4.59 4.01
4.01 3.65
3.65 3.39
3.39 3.19
3.19 3.03
3.03 2.90
All hkl
Summary of observation redundancies by shells:
of reflections with given No. of observations
1 2 3 4 5-6 7-8 9-12 13-19
177 239 426 352 148 7 0 0
93 375 390 323 224 0 0 0
96 365 455 282 206 0 0 0
104 371 395 352 165 0 0 0
93 328 426 324 197 0 0 0
104 336 388 383 187 0 0 0
98 334 323 414 180 0 0 0
118 354 405 372 123 0 0 0
883 2702 3208 2802 1430 7 0 0
I
0
192
41
0
2
1
3
1
3
243
40.
>19
0
0
0
0
0
0
0
0
0
total
134 9
14 
14 04
1387
136 
1398
134 9
1372
1 1032
Surmary of reflections intensities
R linear = SUM ( ABS(I - <I>)) SUM ( 
R square = SUM (I - <I>) * 2 SUM (I 
Chi**2 = SUM (I - <I>) * 2 (Error 
In all sums single measurements are excluded
and R-factors by shells
2) )
2) ) * N / (N-1)
Shell Lower Upper
limit Angstrom
20.00 5.76
5.76 4.59
4.59 4.01
4.01 3.65
3.65 3.39
3.39 3.19
3.19 3.03
3.03 2.90
All reflections
Average
I
2513.6
1108.5
1149.4
727.2
634.7
415.7
160.4
89.8
848.4
Average Norm.
error stat. Chi**2
107.7 72.2 0.808
59.6 47.1 0.978
66.4 52.8 1.162
57.5 50.5 1.152
57.1 51.2 1.231
51.0 46.9 1.118
40.5 39.8 1.052
36.2 35.8 1.004
59.4 49.5 1.065
Linear
R-fac
0 03 
0 056
0 00
0. 102
0. 129
0 .185
0. 34 
0. 500
0 07 9
Square
R-fac
0. 02 9
0. 05 5
0 06 
0. 094
0 104
0. 124
0 310
0. 526
0. 04 
2Table
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Nat ive 2
She 
Lower Upperlimit limit
20.00 5.17
5.17 4.12
4.12 3.60
3.60 3.27
3.27 3.04
3.04 2.86
3.86 2.72
2.72 2.60
All hkl
-ies by shells:)f observations
.8 9-12 13-19 >19
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 - 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
Summary of observation redundant
No. of reflections with given No. c
I 1 2 3 4 5-6 7-
438 475 378 169 175
I
I
I
C
462
34 5
24 
201
17E
291
552
1 143
342(
179
161
200
222
192
77
0
1200
386
4 0
3 56
3 71
3 6 
537
3 86
32 3 9
53 9
558
601
61 
604
470
309
4 17 
393
443
432
406
372
224
96
2744
157
13 
12 
110
6
12
0
799
total
1638
1654
1700
1710
172 4
1619
132 
7 91
12156
Summary of reflections intensities
R linear = SUM ( ABS(I - <I>)) SUM (I) 
R square = SUM (I - <I>) * 2 SUM (I 
Chi**2 = SUM (I - <I>) * 2 (Error 
In all sums single measurements are excluded
and R-factors by shells
2) )
2) ) * N / (N-1)
Shell Lower Upper
limit Angstrom
20-00 5.17
5.17 4.12
4.12 3.60
3.60 3.27
3.27 3.04
3.04 2.86
2.86 2.72
2.72 2.60
All reflections
Average
I
9646.3
4867.1
3066.1
2371.6
705.3
320.3
175.7
132.8
2894.9
Average Norm.
error stat. Chi**2
430.4 275.5 1.640
219.5 147.4 1.875
170.1 130.3 1.751
156.2 127.3 1.555
109.3 103.8 1.322
100.2 98.5 1.131
86.6 85.9 1.167
71.6 71.2 1.204
176.5 135.1 1.513
Linear
R-fac
0. 04 
0 054
0 067
0 07 
0. 17 
0 34 3
0 4 64
0 3 83
0 06 
Square
R-fac
0 04 3
0. 061
0 068
0 067
0. 178
0.418
0. 571
0.470
0 053
3Table
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12+12 (First crystal)
Shell
Lower Upperlimit limit
20.00 5.56
5.56 4.43
4.43 3.88
3.88 3.52
3.52 3.27
3.27 3.08
3.08 2.93
2.93 2.80
All hk1
Summary of observation redundancies by shells:
No. of reflections with given No. of observations
0 1 2 3 4 5-6 7-8 9-12 13-19
706 260 361 100 262 0 0 0 0
521 226 429 117 270 0 0 0 0
523 189 474 105 257 0 0 0 0
504 212 440 115 257 0 0 0 0
474 220 454 112 242 0 0 0 0
515 172 475 108 224 0 0 0 0
544 208 460 84 211 0 0 0 0
681 167 447 105 108 0 0 0 0
4468 1654 3540 846 1831 0 0 0 0
>19
0
0
0
0
0
0
0
0
0
total
983
1042
102 
102 4
102 
97 9
96 3
82 7
787 
Summary of reflections intensities
R linear =.SUM ( ABS(I - <I>)) SUM (I) 
R square = SUM (I - <I>) * 2 SUM (I 
Chi**2 = SUM (I - <I>) * 2 (Error 
In all sums single measurements are excluded
and R-factors by shells
2) )
2) ) * N / (N-1)
Shell Lower Upper
limit Angstrom
20.00 5.56
5.56 4.43
4.43 3.88
3.88 3.52
3.52 3.27
3.27 3.08
3.08 2.93
2.93 2.80
All reflections
Linear
R-fac
0. 02 9
0. 04 
0 04 
0 060
0 059
0. 13 4
0.287
0 42 9
57
Average
I
2894.5
1556.0
1514.2
1005.7
956.1
361.0
163.7
100.1
1095.8
Average Norm.
error stat. Chi**2
147.5 107.1 1.065
88.3 69.1 0.948
86.4 69.4 1.016
68.1 58.0 1.016
70.1 60.6 0.944
56.7 54.6 1.007
54.8 54.1 0.981
51.9 51.7 0.985
78.6 65.9 0.995
Square
R-fac
0 03 
0. 04 
0. 04 
0 057
0. 05 0
0.111
0 24 3
0, 381
0. 04 3
Table 4
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12+12' (Second crystal)
Shell
Lower Upperlimit limit
20.00 5.76
5.76 4.59
4.59 4.01
4.01 3.65
3.65 3.39
3.39 3.19
3.19 3.03
3.03 2.90
All hkl
Summary of observation redundancies by shells:
No. of reflections with given No. of observations
7-0 1 2
688 180 364
568 134 388
539 130 4 14
523 12 1 424
437 134 494
532 125 442
426 1 51 4 97
518 164 4 5 8
4231 1139 3481
3 4 5-6
60 24 16
68 262 27
57 248 3 
62 240 20
58 23 13
62 225 25
62 204 1 8
58 171 22
487 1826 172
-8 9-12 13-19 >19
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
total
86 
87 9
880
867
93 
87 9
932
87 3
710 
Summary of reflections intensities
R linear = SUM ( ABS(I - <I>)) SUM (I) 
R square = SUM (I - <I>) * 2 SUM (I 
Chi**2 = SUM (I - <I>) * 2 (Error 
In all sums single measurements are excluded
and R-factors by shells
2) )
2) ) * N / (N-1)
Shell Lower Upper
Jimit Angstrom
20.00 5.76
5.76 4.59
4.59 4.01
4.01 3.65
3.65 3.39
3 3 93.19
3.19 3.03
3.03 2.90
All reflections
Linear
R-fac
0 03 7
0 056
0. 0 6
0. 078
0. 08 5
0. 12 
0 2 9 3
0 42 4
0 070
Average
I
2700.5
952.4
1054.3
735.3
678.5
466.1
163.0
101.5
847.2
Average Norm.
error stat. Chi**2
114.7 69.2 1.684
50.6 38.8 1.401
61.7 48.8 1.142
58.3 50.5 1.082
59.8 53.4 1.214
59.6 56.0 1.053
51.2 50.6 1.004
53.0 52.8 0.930
63.4 52.5 1.192
Square
R-fac
0. 03 6
0. 051
0 052
0. 06 6
0 070
0 090
0.255
0 4 5
0. 04 
Table 5
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,(First crystal)
Shell
Lower Upperlimit limit
20.00 5.95
5.95 4.75
4.75 4.15
4.15 3.78
3.78 3.51
3.51 3.30
3.30 3.14
3.14 3.00
All hkl
,ncies by shells:
of observations
7-8 9-12 13-19
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
Summary of observation redunda
No. of reflections with given No.
0
617
511
471
443
472
4 30
4 90
4 5
3 889
1
171
103
84
96
112
126
133
127
9 52
2
34 
406
44 
432
412
409
399
36 
3209
3
21
59
57
22
50
50
58
4 9
366
4
233
233
217
249
219
204
185
195
173 
5 6
0
0
0
0
0
0
0
0
0
>19
0
0
0
0
0
0
0
0
0
total
76 6
801
803
799
79 3
78 9
77 
73 6
6262
Summary of reflections intensities and R-factors by shells
R linear = SUM ( ABS(I - <I>)) SUM (I) 
R square = SUM (I - <I>) * 2 SUM (I * 2 
Chi**2 = SUM (I - <I>) * 2 (Error * 2 ) * N / (N-1)
In all sums single measurements are excluded
Shell Lower Upper
limit Angstrom
20.00 5.95
5.95 4.75
4,75 4.15
4.15 3.78
3.78 3.51
3.51 3.30
3.30 3.14
3.14 3.00
All reflections
Linear
R-fac
0. 04 
0. 070
0. 078
0 086
0 103
0. 1 4
0 184
0 3 92
0. 085
Average
I
1567.3
644.0
665.7
521.5
398.4
399.2
196.5
86.3
561.2
Average Norm.
error stat. Chi**2
79.6 57.4 1.515
40.4 33.5 1.424
45.9 39.3 1.545
45.1 40.8 1.269
44.8 41.8 1.105
47.5 44.3 1.102
43.3 42.3 1.014
41.2 41.0 0.942
48.4 42.5 1.247
Square
R-fac
0 04 3
0. 069
0. 07 
0. 078
0 092
0 086
0. 14 6
0. 34 
0 064
11+1 I
Table 6
119
(Second crystal)
Shell
Lower Upperlimit limit
20-00 5.56
5.56 4.43
4.43 3.88
3.88 3.52
3.52 3.27
3.27 3.08
3.08 2.93
2.93 2.80
All hk1
Summary of observation redundancies by shells:
No. of reflections with given No. of observations
0 1 2 3 4 5-6 7-8 9-12 13-19
251 245 477 174 546 22 0 0 0
166 165 483 134 597 44 0 0 0
140 160 503 142 583 41 0 0 0
127 164 518 133 572 48 0 0 0
133 119 518 150 573 36 0 0 0
71 178 552 144 543 36 0 0 0
163 161 508 158 511 39 0 0 0
285 291 431 193 295 23 0 0 0
1336 1483 3990 1228 4220 289 0 0 0
>19
0
0
0
0
0
0
0
0
0
total
14 64
142 3
1429
14 3 
13 96
14 53
1377
123 3
112 0
Summary of reflections intensities
R linear = SUM ( ABS( - <I>)) SUM (I) 
R square = SUM (I - <I>) * 2 SUM (I 
Chi**2 = SUM (I - <I>') * 2 (Error 
In all sums single measurements are excluded
and R-factors by shells
2) )
2) ) * N / (N-1)
Shell Lower Upper
limit Angstrom
20.00 5.56
5.56 4.43
4.43 3.88
3.88 3.52
3.52 3.27
3.27 3.08
3.08 2.93
2.93 2.80
All reflections
Average
I
2414.9
1050.8
936.5
621.2
561.8
210.0
110.9
70.2
766.2
Average Norm.
error stat. Chi**2
95.9 51.5 1.837
48.5 34.3 1.527
48.9 37.8 1.273
43.9 38.1 1.146
45.0 39.6 1.103
37.1 36.1 1.012
37.1 36.7 0.997
39.1 38.9 0.995
49.8 39.2 1.246
Linear
R-fac
0 042
0.054
0.060
0 073
0 083
0.168
0 3 14
0 4 73
0.070
Square
R-fac
0. 042
0. 055
0.058
0 065
0 064
0. 136
0.259
0 4 6
0 052
7
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CHAPTER 4
Crystal Structure of MyoD bHLH Domain Bound
to DNA: New Perspectives on DNA Recognition
and Transcriptional Activation
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Abstract
The crystal structure of a MyoD basic-helix-loop-helix (bHLH)
domain-DNA complex has been solved and refined at 28 A
resolution. This structure: proves that bHLH and bHLH-leucine
zipper (bHLH-ZIP) proteins are remarkably similar; helps us
understand subtle differences in binding preferences for these
proteins; and has surprising implications for our understanding of
transcription. Specifically, Ala 1 4 and Thr 1 1 5, which are
required for positive control in the myogenic proteins, are buried at
the protein-DNA interface. These residues are not available for
direct protein-protein contacts but they may determine the
conformation of Arg 1 1 1. Comparisons with Max suggest that the
conformation of this arginine - which is different in the two
structures - may play an important role in myogenic transcription.
Introduction
Members of the MyoD family of bHLH proteins (MyoD, Myf-S,
MRF4, and myogenin) are transcriptional activators that play a
central role in determining muscle cell identity (Weintraub, H.,
1993; kudnicki et al., 1993). The basic region mediates DNA
binding, and MyoD - like other members of the bHLH superfamily -
binds to DNA sites with the consensus sequence CANNTG (Blackwell
and Weintraub, 1990). The helix-loop-helix domain mediates
dimerization: MyoD forms homodimers and also forms heterodimers
with members of the E2 class of bHLH proteins. The crystal
structure of the Max.bHLH-leucine zipper-DNA (bHLH-ZIP-DNA)
complex (Ferr6-D'Amar6 et al., 993) provided an initial framework
for understanding the helix-loop-helix proteins. The crystal
structure of a truncated upstream stimulatory factor bHLH-DNA
complex (the zipper region which is normally present in this protein
was deleted for crystallization) has provided further information
(Ferrd-D'Amard et al., 1994). However, there still are important
questions about family/subfamily relationships among the bHLH
proteins and about subtle differences in binding site preferences.
A particularly intriguing aspect of MyoD biology that has not been
understood is the observation that certain mutations in the basic
region ("positive control" mutations) bind normally to DNA, but fail
to activate transcription.
We have determined the crystal structure of a complex that
contains the bHLH domain of MyoD with its preferred binding site.
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Even though Myol) (bHLH) and Max (bHLH-ZIP) belong to different
subfamilies and have limited sequence identity 25%) in their bHLH
regions, we find that these complexes are remarkably similar.
Comparing and contrasting these structures: 1 ) emphasizes the
remarkable overall conservation of the bHLH fold, 2 helps us
understand subtle differences in the dimerization and binding site
preferences of the bHLH and bHLH-ZIP proteins, and 3 suggests how
critical residues in the basic region of Myol) may contribute to
transcriptional activation.
Results and Discussion
Overall Structure of the MyoD-DNA Complex
We have solved the structure of a complex that contains the
bHLH domain of Myol) and a DNA fragment with an optimized binding
site (Blackwell and Weintraub, 990; Figure 1. Myol) binds to this
site as a dimer, and the asymmetric unit of the crystal contains
two copies of this MyoD-DNA complex. We find that the overall fold
of the bHLH domain is strikingly similar to that observed in Max and
USF. Each Myol) monomer, which includes residues 102 to 166,
forms two long alpha-helices connected by an eight residue loop.
The first helix contains the basic region and the region originally
identified as Hi; the second helix corresponds to the region
identified as H2 (Figure 2. As observed in the Max complex, the
basic region fits into the major groove, and each monomer of Myol)
makes identical DNA contacts. The helical regions H and H2 are at
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the dimer interface and participate in forming a parallel, left-
handed, four-helix bundle (Figure 2 Even though Max and MyoD
belong to different subfamilies (Max is a bHLH-ZIP protein), we find
that the bHLH regions of these proteins are very similar: if we
exclude the loops, these structures can be superimposed with a
1.2 A rms distance between corresponding alpha carbons. The two
copies of the Myol) complex that are present in the asymmetric unit
of our crystal provide a useful control for our structural analysis
and comparison. Superimposing these two MyoD complexes shows
that they have very similar structures and provides an internal
check on the consistency of our models.
The Basic Region and DNA Recognition
Most of the known bHLH proteins recognize sites of the form
CANNTG, and studies of the Max-DNA and upstream stimulatory
factor-DNA complexes have provided an initial description of these
interactions. As observed with Max, residues in the basic region of
Myol) make most of the DNA contacts (Figures 2 3 and 4 Glu 1 1 8
plays an especially important role in recognition. One of the side
chain oxygens accepts a hydrogen bond from the N4 of base 5
(with distances ranging from 28 - 31 A in the four different
monomers in our crystal). The other oxygen makes a weak hydrogen
bond to the NG of base 3-5 - 38 A). Finally, the carboxylate
group also makes a water-mediated contact with the N4 of base C8'
and a water-mediated contact with the N7 of base A4. The side
chain conformation of Glu 1 1 8 appears to be stabilized by salt
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bridge interactions with Arg 21, which is located in the next turn
of the alpha-helix. Arg 21, in turn, contacts the phosphate of 5
(Figures 3 and 4.
Residues in the basic region of MoD also contact the
conserved T and G of the bHLH binding site, and Arg 1 1 1 [which will
have a central role in our later discussion of positive control] plays
a very important role in making these contacts. Specifically, it
1) donates a hydrogen bond to the N7 of base G1 O' 2.6 - 31 A),
2) makes a water-mediated contact to the 06 of base G1 O', and
3) contacts a phosphodiester oxygen at position G1 O'. Finally, the
Arg 1 1 1 side chain hydrogen bonds to the hydroxyl group of Thr 1 1 5,
which, in turn, uses its gamma carbon to make hydrophobic contacts
with the methyl group of T9' (the methylene groups of the critical
Glu 1 1 8 side chain also help to form a hydrophobic pocket at this
position). In addition, Thr 1 1 5 donates a hydrogen bond to a
phosphodiester oxygen at position T9'.
A number of other residues makes important phosphate
contacts (Figures 3 and 4 There are three critical residues in the
basic region: Arg 1 7 contacts phosphates at positions C2 and 3
(Arg 1 7 may also have an electrostatic interaction with the N of
base A3, but it is too far away 4.0 - 44 A) for a direct hydrogen
bond). Arg 1 1 0 contacts a phosphate at position C2 and also
contacts the terminal -OH at position T1. [We presume it could
contact a phosphate at this position, but our synthetic DNA
fragment has a terminal -OHJ Arg 1 9 makes phosphate contacts at
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positions G7' and CK Several residues outside of the basic region
also make phosphate contacts: Asn 126 (from helix 1) contacts
position AW, Arg 143 (in the loop) contacts position C5', and
Lys 146 (from helix 2 contacts positions C5' and AW. In all, each
Myol) monomer contacts a total of ten positions on the DNA
backbone.
Our structure of the MyoD complex raises a number of
interesting questions about recognition of the central base pairs.
Selection experiments reveal that MyoD and myogenin have limited
specificity for the central two base pairs, although they can
discriminate against the sequences CACATG and CA.MTG (Figure 1 c;
Blackwell and Weintraub, 1990; Wright et al., 1991). MyoD does not
make any direct contacts with the central bases, but the crystal
structure shows a water mediated hydrogen bond between Glu 1 1 8
and the N4 of base CK It seems possible that MyoD's discrim-
ination of the central bases may involve the indirect readout of
subtle changes in the DNA conformation and/or additional water-
mediated interactions (Otwinowski et al., 1988) not readily
identifiable at this level of resolution. There may be fundamental
differences in the way that bHLH and bHLH-ZIP proteins contact the
central base pairs. Max has an arginine (corresponding to Leu 22 of
MyoD) that contacts the N7 atom of the guanine CAC.QTG and helps
explain the sequence preference. In contrast, Leu 22 of Myol) is
not in a position to make any base-specific contact, and it is
interesting that bHLH proteins typically have a hydrophobic amino
acid at this position, while bHLH-ZIP proteins usually have an
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arginine. Moreover, genetic studies have shown that changing Leu
122 in Myol) to an arginine changes the preferred binding site from
CAMTG to CACQTG (Blackwell et al., 1993).
Selection studies also show that the myogenic proteins prefer
purines on the 5' flanking side of the site (BACANNTG) and
pyrimidines on the 3 flanking side (CANNTGIY). The crystal
structure shows some contacts with the 5' flanking residues that
may - directly or indirectly - be responsible for these preferences.
As mentioned previously: Glu 1 1 8 makes a water mediated contact
to the N7 of base A4; Arg 1 7 makes phosphate contacts at
positions C2 and A3, and Arg 1 7 may have a weak interaction with
the N7 of base A3. The Arg residue at position 1 7 is highly
conserved in the bHLH proteins and clearly is important for binding.
Changing this residue to leucine (which appears at the
corresponding position in Max) knocks out DNA binding (Van Antwerp
et al., 1992). Max is rather different in this region: There are no
contacts with the flanking bases, binding site selections show no
sequence preferences at these positions (Blackwell et al., 993),
and the Leu at position 1 7 does not make any DNA contacts.
Structure of the DNA
The crystal structure shows that the binding site is
essentially B-DNA, but there are a few distinctive features. First,
we note that base pairs A6:T9' and A6':T9 - which make critical
contacts with Glu 1 1 8 - are buckled. There also are two distinctive
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global features of the Myol) DNA. First, we note that the base pairs
of Myol) have an inclination of about degrees, whereas the base
pairs are essentially perpendicular to the helical axis in standard
B-DNA. Second, there are interesting differences in groove width.
The majpr groove is rather narrow (1 0.8 A in MyoD vs. 12.3 A in 13-
DNA) and the minor groove is rather wide (8.1 A in Myol) vs. 48 A in
B-DNA). It is interesting that the Max DNA has similar
characteristics. Although these features were not discussed in the
original report, the Max DNA has buckled base pairs at positions
A6:T9' and A6':T9 a wide minor groove, and a significant inclination
of the base pairs. In spite of these distinctive features of the MyoD
DNA, the overall structure is essentially B-form DNA, and we find
that the DNA is relatively straight. This is consistent with
biochemical experiments which had indicated that binding of MyoD
does not significantly bend the DNA (Fisher, D., personal
communication).
Dirner Formation in bHLH Proteins
Comparing the Max and MyoD structures helps us understand
dimer formation in the bHLH and bHLH-ZIP proteins. As mentioned
before, the structures of the bHLH domains of Max and MyoD are
remarkably similar, and a more detailed comparison shows that
they have conserved packing arrangements for the hydrophobic
residues in the core of the four-helix bundle. All of the hydrophobic
residues in Max have structural counterparts in MyoD, and
mutagenesis experiments confirm the importance of these residues
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for dimer stability (Davis et al., 1990; Winter et al., 992;
Voronova and Baltimore, 1990). These similarities are particularly
noteworthy given the distinctive dimerization specificities of the
bHLH and bHLH-ZIP proteins. For most bHLH-ZIP proteins (including
Max and myc ), the entire bHLH-ZIP region is needed for efficient
dimerization and DNA binding (Kato et al., 1992; Smith et al., 1990),
and these proteins usually fail to dirnerize with bHLH proteins. To
understand why the bHLH-ZIP proteins need a leucine zipper for
effective dimerization and DNA binding, we looked for differences
in the helix-loop-helix dimer interfaces of Max and Mol). We first
calculated the surface areas buried upon dimer formation and found
that these are essentially equal (the buried surface area is 2%
greater for the Myol) bHLH domain than for the Max bHLH domain).
Comparing the dimer interfaces in more detail shows interesting
differences that might help us understand differences in dimer
stability, but mutagenic analysis may be needed to rigorously
determine the energetic significance of individual contacts.
Although the four-helix bundles are very similar, there are
significant structural differences in the loop regions of Max and
MyoD. More generally, comparing sequences of bHLH proteins shows
that the loop regions vary in composition and length (Figure 1 ) and
swap experiments show that these loops are not always
functionally interchangeable among bHLH proteins (Pesce and
Benezra, 1993). Finally, in comparing the helix-loop-helix regions
of Max and MyoD, we noted a curious cavity between the four helix
bundle and the DNA. This cavity, which is just above the central
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base pairs in the MyoD and Max structures, is large enough to
accommodate a small molecule about the size of a nucleotide, but
we do not yet know whether the cavity has any special structural or
functional significance.
On the whole, a comparison of Max and MyoD complexes shows
that the bHLH domain is a very well conserved motif, and the
leucine zipper provides a simple way of extending the dirner
interface. In fact, superimposing the Max and MyoD structures
indicates that the C-termini of the H2 helices of MyoD could readily
be extended with a leucine zipper. As proposed in the original
report on the Max complex (Ferr6-D'Arnar6 et al., 993), the overall
conservation of the bHLH fold (and the corresponding dirner
interface) reflects the inherent stability of this structure and
allows for regulatory networks that can be controlled via a set of
competing hornodirner and heterodimer interactions. The Max and
MyoD structures may provide a reasonable basis for modeling other
bHLH domains and for modeling heterodimer formation. (Since this
fold is so well conserved in different bHLH proteins, it seems
plausible to assume that it will be conserved as the heterodimers
form). In this regard, we note that Ellenberger et al. (personal
communication; Ellenberger et al., 1994) have recently solved the
structure of the E47 hornodirner. Combining our structures should
provide a plausible basis for modeling the MyoD-E47 heterodirner,
which may be the biologically active species.
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Myogenic Transcription
Previous studies of MyoD have shown that the bHLH domain is
necessary and sufficient for DNA binding and muscle cell
conversion. In addition, a region of about 50 residues at the N-
terminus can function as a transcriptional activation domain
(Weintraub et al., 1991 ). However, there also are several positions
in the basic region where mutations can alter transcriptional
activation without affecting DNA binding. Ala 1 4 is one of the
critical positions where mutations can give such a "positive
control" phenotype (Bengal et al., 1994). "Swap experiments" which
mix and match segments from MyoD and El 2 also have been used to
determine which residues are required for transcriptional
activation. These experiments highlight the roles of Ala 1 4 Thr
1 1 5 and Lys 124, which are conserved in all of the myogenic
proteins. Remarkably, introducing just these three residues into
comparable positions in El 2 allows that protein to function as a
myogenic activator (Davis and Weintraub, 1992).
Examining the MyoD-DNA complex shows that Lys 124 is
exposed on the surface and thus could readily participate in
protein-protein interactions (with the activation domain or with
the transcriptional apparatus). However, Ala 14 and Thr 1 1 5 are
buried in the major groove (Figure 5a), and this raises an
interesting question: How can these two residues participate in
transcriptional activation when they are not exposed at the
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surface? Could they have subtle, indirect effects on the overall
structure of the complex?
Although other scenarios are possible, comparing the Max and
MyoD structures suggests a plausible hypothesis about how residues
1 1 4 and I might exert critical - but indirect - effects that could
be "relayed" to the surface of the complex. In particular, we note
that Arg 1 1 1 has very different conformations in these two
complexes, and it appears that residues 14 and 1 1 5 help to
determine the conformation of the arginine (Figure 5b). In the MyoD
complex, Arg 1 1 1 is buried in the major groove and contacts the 7
of base G1 0. (Thr 1 1 5 makes a base contact and a backbone contact;
the small size of Ala I 4 helps provide room for the arginine to fit
in the groove.) In the Max complex, Arg 1 1 1 has a very different
conformation: It swings out of the major groove and makes a
phosphate contact. (His 1 4 of Max contacts the N7 of base G1 0 and
appears to displace the arginine side chain).
Sequence comparisons are consistent with the general notion
that Arg 1 1 1 may need to be buried for myogenic transcriptional
activation: Most bHLH proteins - with the notable exception of those
involved in myogenesis - have a His or Asn residue at position 1 4.
As in Max, this residue could contact G1 0 and force Arg 1 1 1 out of
the major groove (in a way that might interfere with activation of
muscle-specific genes). We are currently undertaking mutagenesis
experiments to test for interactions among the residues at
positions 1 1 1, 14 and 1 1 5. In particular, we are looking for
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second-site revertants to the positive control mutants, and we
predict that at least some of these revertants will be found at
position 1 1 1. Preliminary results are consistent with this model:
Thus, our model predicts that substituting a small amino acid, such
as glycine, at position 1 4 would still accommodate Arg 1 1 1 in the
major groove and give wild type MyoD activity. This has recently
been confirmed (J. Huang, P.C.M., M.A.R., C.O.P., H.W., unpublished
results). Finally, we note that the structure of the E47-DNA
homodimer complex (which does not activate myogenesis is
consistent with our hypothesis. In the recently solved structure of
the complex, Arg 1 1 1 has a conformation similar to that seen in Max
(Ellenberger et aL, personal communication; Ellenberger et al.,
1994).
Conclusions
This crystal structure of the MyoD-DNA complex gives
important new insights about the bHLH proteins in general and about
the myogenic proteins in particular. Specifically, we note that:
1) the structure of the bHLH domain of MyoD and of the
corresponding region of Max (a bHLH-ZIP protein) are remarkably
similar. Thus, it appears that the bHLH structure is very well
conserved in spite of the modest sequence identities between the
Max and MyoD domains 25% identity) and that the presence of the
leucine zipper does not significantly affect the structure of the
bHLH domain. 2 Our crystal structure helps us understand subtle
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differences in the site specificities of the bHLH proteins. 3 The
structure shows that Ala 14 and Thr I 5, two of the key residues
implicated in transcriptional activation, are buried in the major
groove and thus, unlikely to be involved in any direct protein-
protein interactions. These residues may be required because of
indirect effects on the conformation of Arg 1 1 1 (introducing other
residues at positions 1 4 and 1 1 5 may force Arg 1 1 1 out of the
major groove and thereby interfere with transcriptional activation).
Experimental Procedure's
The peptide used in our studies contains residues 102-166 of
the mouse MyoD protein (which is identical to human MyoD in this
region) and three extraneous residues (MEL) that were added at the
N-terminus during cloning (Figure a). We also replaced Cys 3 5
with Ser to simplify crystallization attempts: earlier experiments
had shown that the Cys residue can readily form intermolecular
disuffide bonds which knock out DNA binding activity (Starovasnik
et al., 1992; Ma and Pabo, unpublished data). [NMR studies also have
shown that this oxidized peptide (Starovasnik et al., 992) forms an
antiparallel four-helix bundle, but the biological relevance of this
form is unclear.] We find that replacing the Cys residue by Ser did
not noticeably affect the biological properties of the peptide. The
peptide was expressed in E. coli and purified to homogeneity by
reverse phase chromatography using Vydac C4 and C1 8 columns.
The DNA used in the crystallization attempts was synthesized by
standard phosphoramidite chemistry and purified by reverse-phase
HPLC and ion exchange chromatography. A series of different DNA
duplexes was tested during our crystallization attempts (Jordan et
al. 1985) using the vapor diffusion method. The best crystals used
a 14 bp DNA duplex (Figure 1 b) and grew at 22 from drops
containing 10%-1 5% PEG 3500, 1 00 mM Tris-HCI, pH 8.5, 1 OmM
NaCitrate, 20 mM BaC12- Crystals grew over the course of a few
days with a final size of approximately 03 mm x 03 mm x 04 mm.
The crystals belong to the space group P21212 and have unit cell
dimensions of a=222.8 A, b=70.8 A, c=30.0 A with two protein
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dimer-DNA complexes in the asymmetric unit 55% solvent
content); each complex has a non-crystallographic two-fold axes.
Isomorphous derivatives of the complex were obtained by using DNA
duplexes with 5-iodouracil substituted for thyrnine: 1 ) at positions
1 1 and 1 1' and 2 at positions 2 and 2 (Figure 1 b). Two crystals
were used for each derivative, but each crystal was treated
separately during heavy atom parameter refinement and phasing.
Diffraction data were collected at 22 'C using a Rigaku
RAXIS-IIC imaging plate area detector. Diffraction from the
crystals was anisotropic, with the best diffraction (about 26 A)
along the DNA axis. Data were processed with DENZO/SCALEPACK
(Z. Otwinowski, personal communication), and DSCALEAD (M. Rould)
was used for local scaling of the derivative data sets to the native
data. Heavy atom positions were determined from a combination of
isomorphous and anomalous difference Patterson maps; the program
HASSP (Terwilliger et al., 1987 was used to help determine the
initial positions. The positions and occupancies of the heavy atoms
were refined using the program REFINE (S.E.R.C., 1979) on centric
reflections for each of the individual derivatives, and then by
cross-phased refinement with PHARE (S.E.R.C., 979) in which each
derivative is refined using parental phases determined solely from
the native and other derivatives (Table 1). An initial MIR map at
3.0 A revealed clear density for the DNA, the alpha-helices and part
of the loop region. One round of solvent flattening (Wang, B.C.,
1985) significantly reduced the noise level and improved the
continuity of the electron density in the loop region. The heavy
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atom parameters were then refined again using the solvent-
flattened phases as the parent phases (Rould et al., 1992), and
another MIR map was calculated. Finally, this map was averaged
about the two non-crystallographic symmetry axes to give a
solvent-flattened, four-fold non-crystallographic symmetry-
averaged MIR map that allowed us to see most of the side chains
(Figure 4b).
Idealized B-form DNA (generated by INSIGHT) was placed in
the clear MIR density and each nucleotide adjusted to improve the
fit. The alpha-helical regions were modeled as polyalanine helices
and the loop region was fit with an extended polypeptide chain.
Using this initial framework, a model with side chains was built
into the MIR map using the program FRODO (Jones, 1978) and this
model was refined with XPLOR (Brunger et. al, 1987; Brunger,
1992a) using positional refinement and simulated annealing. Before
any refinement, 1 0% of the reflections were removed for cross-
validation (free R-factor). We monitored the free R-factor during
all stages of rebuilding and refinement (Brunger, 1992b) and
changes in the free R factor were used to evaluate the effects of
symmetry restraints and to make other basic decisions about the
refinement strategy. Strict noncrystallographic symmetry was
applied during the first rounds of refinement at 30 A and 29 A;
tightly restrained noncrystallographic symmetry was used in the
later stages. In order to correct for anisotropic diffraction, data
were locally scaled against calculated structure factors using the
program DSCALEAD. The conformations of the side chains and bases
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were checked using simulated annealing omit maps (Brunger,
1992a), as well as positionally refined omit maps. During the last
rounds of refinement, data up to 26 A were included, although the
limited completeness and anisotropy of diffraction of the higher
resolution shells effectively limits the resolution of our structure
to about 28 A. The residues N-terminal to 105 are disordered in all
but one monomer (where it happens to be ordered because of crystal
packing contacts). During the last stages of model rebuilding, 25
water molecules were added and accepted because they met the
following strict criteria: 1) they were found at the interface of the
basic region and the DNA, and hence were of poten tial biological
interest; 2 they appeared with strong density in F-Fc maps in
similar positions in at least two of the four monomers; 3 they
participated in at least one hydrogen bonded interaction (most
participated in at least two) and 4 they refined to an isotropic 13-
factor of no more than 60 A2 with unit occupancy. Tightly
restrained individual B-factors were used in the final stages of
refinement. In addition to refinement with XPLOR, we also used
positional refinement with the program TNT (Tronrud et al., 1987).
We believe that TNT has a more accurate stereochemical dictionary
for DNA and that XPLOR has a more accurate stereochernical
dictionary for proteins (Engh and Huber, 991 ). Hence, our final
model of the MyoD-DNA complex is a chimera which uses the DNA
from TNT and the protein from XPLOR. The crystallographic R factor
of the final model is 25.3% using all of the data and 22.4% using
data with I > 2a. The corresponding free R values are 33.0% and
30.4% respectively. The rms deviation in bond lengths and bond
angles for the protein are 0.008 A and 1289 degrees and 00 3 A
and 3270 degrees for the DNA.
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Table Leaends
Table 1: Data collection, phasing, and refinement
statistics.
These statistics group together data from a number of computer
programs, used at different stages of the structure determination.
The data collection and reduction statistics are from DENZO and
SCALEPACK (Z. Otwinowski). The phasing statistics are from
REFINE and PHARE from the CCP4 package (S.E.R.C., 1979). The
refinement statistics are from XPLOR (Brunger, 987, 1992a) and
TNT (Tronrud et al., 1987).
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Figure 1: Sequences of MyoD bHLH domain and DNA
fragment used in cocrystallization
I
Figure la
Sequence alignment of MyoD with other members of the bHLH
subfamily, alo ng with sequence of the bHLH-ZIP protein Max. Amino
acids are given in one-letter code and conserved residues are
denoted by stippled boxes. The Myol) numbering is used throughout
the alignment and the text.
Figure lb
Sequence of the symmetric DNA duplex used for crystallization,
showing the numbering scheme used in this paper. The thyrnine
bases which were replaced by 5-iodo-uracil in making isomorphous
derivatives are highlighted.
Figure c
Summary of selection data from optimizing the DNA binding sites
for MyoD and myc (Blackwell and Weintraub, 1990; Blackwell et al.,
1993). The residues CAxxTG, which were not randomized in these
experiments, are highlighted.
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Figure 2 Overview of the MyoD-DNA complex
Figure a
In this figure, the 14 bp DNA site is shown in light blue, with the
nucleotides CA--TG highlighted in violet. The basic region is
yellow, as are the side chains which make base-specific and
phosphate contacts to the DNA. The helix-loop-helix region of MyoD
is shown in red.
Figure was generated using Insight 11 software (1310SYM
Technologies, Inc.).
Figure b
Sketch of the MyoD-DNA complex in the same orientation as in
Figure 2a. The alpha-helices are represented as cylinders and a few
residue numbers are given for reference. The sugar-phosphate
backbones of the DNA are represented with ribbons.
Figure 3 Summary of base and phosphate contacts
Sketch summarizing the base and phosphate contacts made by
one monomer of MyoD. The contacts made by the other monomer in
the dimer are not shown, but they involve identical contacts at
symmetry-related positions on the opposite strand of the DNA (the
symmetry axis is shown as a black oval between bases G7 and G7').
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The DNA is represented as a cylindrical projection with phosphates
indicated by circles. Critical CA--TG base pairs are indicated with
heavier lines; bases and phosphates contacted by one monomer are
shaded. As noted in the text, there are no ' terminal phosphates on
our DNA, and Arg 1 1 0 makes a contact to the 05' of T1.
Figure 4 Interactions of the Myol) basic region with DNA
Figure a
Stereo diagram showing the key contacts made by one of the basic
helices with its binding site. For reference, we have also shown the
alpha-carbon trace of the other basic helix. The view is similar to
that in Figure 2 but the complex has been rotated slightly in order
to better show the side chain-base contacts. Base-specific
contacts are made by Arg 1 1 1, Thr 1 1 5, and Gu 1 1 8. Phosphate
contacts are made by Arg 1 1 0, Arg 1 1 1, Thr 1 1 5, Arg 1 7 Arg 1 9,
and Arg 121. Water-mediated contacts are made by Arg 1 1 1 and Glu
1 1 8. Some of the critical hydrogen bond contacts are represented
as dashed lines (I 1 1 RG1 ', 1 1 8E-CS, 1 1 8E-A6, 21 R-C5, 21 R-
1 1 8E).
Figure 4b
Solvent-flattened MIR electron density map at 30 A, showing the
interface between the basic region and the DNA (looking down the
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axis of the DNA). The sidechain residues of Arg 1 1 1, Glu 1 1 8, and
Arg 121 are highlighted in magenta, while the peptide backbone and
side chains for the other residues in the region 1 1 1 to 21 are
shown, as are the DNA nucleotides CS and G1 '.
Figure 5: Conformation of residues involved in positive
control
Figure Sa
Figure highlights critical residues implicated in positive control.
For clarity, only one basic helix and one half of the DNA site (Le 7
base pairs) are shown, and the view is looking down the axis of the
basic helix. Residues 108 to 124 are shown in light blue and the
side chains of the positive control residues - Ala 14, Thr 1 1 5, and
Lys 124 - are shown in red. The DNA is shown in yellow, and the
sugar-phosphate backbones are highlighted with ribbons.
Figure b
Superposition of the alpha carbon trace of the basic regions from
MyoD and Max showing the side chains of residues Arg 1 1 1, Ala 14,
and Thr 1 1 5 from MyoD and the corresponding residues from Max:
Arg25,His28andAsn29- WealsoshowtheC5andGlO'
nucleotide pair from MyoD and the corresponding nucleotides from
Max. The view is looking down the axis of the DNA, as in Figure 4b.
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The residues and nucleotides from MyoD are shown in red; those
from Max are shown in light blue.
Figures were generated using Insight 11 software (BIOSYM
Technologies, Inc.).
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Statistics for Data and Derivatives
Derivative 11+111
First Crystal Secmd Crystal
3.0 2.8
QLnvative 12+12'
First Crystal Second Crystal
Z8 Z9
Native2
2.6
Nativel
2.9Resolution (A)
30,065
12,156
6.5%
78.0%
20,456
7871
5.7%
63.8%
17.8%
16,094
7105
7.0%
62.7%
23.4%
19,412
6262
8.5%
61.7%
26.8%
31,193
11,210
7.0%
89.4%
26.2%
Measured reflections 37,898
Unique reflections 11,032
Rsyrn a 7.9%
Data completeness 97.8%
Mean isomorphous difference b
Phasing statistics. 20 to 3.0 A
Cullis R. factor c
Phasing power d
Mean figure of meet . 0.65 e
.52
1.69 
.52
2.12
.51
2.05
.52
2.55
1:hA 1 ki' h 1 /':hlihi where Iki is mean intensity
of the i observations of reflection h
b 1: 1 'PH - IP 1 /Z <'> where PH and Ip are the derivative
and native intensities, and <1> is [IpH + Ip] /2
c I I de, - F,.t I - H(ck I 1 I der - Fnt I for centric
reflections, where FH(cjc) is the calculated heavy
structure factor
d rms H/E, where E - residual lack of closure error
I After solvent flattenin& Mean figure of merit=0.75
f Engh and Huber 1991) dictionary for protein:
parhmdx.pro in XPLOR
9 TNT dictionary for DNA
Refinement: 20 to 2.8 A All data I I
Rfactor M 25.3% 22
Free Rfactor 33.0% 30
Reflections 10585 89
Total number of atoms 3984
R.m.s. bond length (A) 0.008 (protein)f
R.m.s. bond angle (degrees) 1.3 (protein)f
R.m.s difference in B between bonded atoms
I >2m
.4%
1.4%
63
0.013 (DNA)9
33 (DNA)9
238 A2
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CHAPTER 
Structural Basis for Dimer Stabilization
and Dimer Specificity for MyoD
and other bHLH Proteins
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Like the UIP proteins, the bHLH and bHLH-ZIP proteins bind
DNA as dimers, with each monomer binding to half of the DNA site
(Ellenberger, T., 1994). Since the bIP, bHLH, and bHLH-ZIP proteins
can form homodirners as well as heterodimers, and since these have
different affinities and specificities for the DNA, dimerization
plays an important role in determining the DNA binding activity of
these proteins. With the bHLH and bHLH-ZIP proteins, we are
fortunate in having four structures of homodimers bound to DNA: 1)
the Max bHLH-ZIP domain (Ferr6-D'Arnar6 et al., 1993) 2 the USF
bHLH domain in which the leucine zipper which is normally present
in the protein has been deleted for crystallization purposes (Ferr6-
D'Amar6 et al., 994) 3 the E47 bHLH domain (Ellenberger et al.,
1994); and 4 the MyoD bHLH domain. In this chapter, the structural
basis of dimerization for the bHLH proteins is addressed. We first
describe the dimer interface for the MyoD bHLH domain bound to
DNA, concentrating on aspects of the structure that were not
discussed in detail in Chapter 4 Next, we examine the structure of
a model of the MyoD-E47 heterodimer in which the MoD homodimer
coordinates and the E47 homodimer coordinates (kindly provided by
T. Ellenberger and SC. Harrison) were combined to generate a model
of the heterodimer. In this section, we address the question of why
the MyoD-E47 heterodimer may be a more stable structure than the
MyoD hornodimer. In the last section of this chapter, we will look
at other members of the bHLH family of proteins and use what we
have learned from the Max, USF, E47 and MyoD structures to suggest
plausible determinants for dirnerization specificity within this
group of proteins.
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A. The Myol) bHLH Homodimer
We have grouped the contacts at the dimer interface of the
MyoD homodimer into four major regions: first, a hydrophobic core
in the interior of the four helix bundle; second, region A at the
interface between helix of one monomer and the apposing helix 2
of the dimeric partner; third, region where the C-terminus of
helix 1, the N-terminus of the loop, and helix 2 residues from both
dimeric partners come together; and fourth, region C, near the part
of the hydrophobic core closest to the DNA, where helix I first
crosses helix 2 of the same monomer. We describe each one of
these four regions in turn.
1. The Core
In MyoD, this region consists of nine residues from each
monomer (Figures a and 2a). Most of these residues are highly
conserved over all bHLH and bHLH-ZIP proteins, and almost all of
these residues are hydrophobic in character. Isoleucine and/or
leucine residues are particularly well-represented and well-
conserved, both within the HLH region itself, as well as in the
zipper region of bHLH-ZIP (Beckmann and Kadesch, 1991; Dang et al.,
1 991 ). As mentioned earlier, our discussion will focus on the bHLH
region (see (Ellenberger, 1994) for a discussion of zipper regions in
bZIP and bHLH-ZIP proteins). The parallel, left-handed, four-helix
bundle, formed by helix and helix 2 of each monomer, was first
described in the report on the Max structure (Ferr6-D'Amar6 et al.,
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1993). The structure of the Max-DNA complex showed that all of
the conserved hydrophobic residues from the bHLH region are found
within the core of the four-helix bundle. The residues within the
hydrophobic core of MyoD form structural counterparts to those
residues in Max. Val 125 and Phe 29 from helix and Ile 149 and
Leu 1 50 from helix 2 are in the region of the core closest to the
DNA, near a cavity located directly above the central base pairs of
the DNA (see Chapter 4 for more on the cavity). Leu 132 of helix ,
together with Ala 53 and Ile 54 from helix 2 form the middle of
the core. The carboxy terminus of the core is composed entirely of
residues from helix 2 Ile 157 and Leu 160, which pack in an
arrangement similar to the side-by-side packing of coiled-coils
(Ellenberger, 1994). Outside of the core, there are two more
hydrophobic residues in helix 2 Leu 63 and Leu 164, which also
pack in a side-by-side arrangement. These residues contribute to
the stability of the C-terminus of the four-helix bundle in the MyoD
structure (Figure 3, but since these residues are not well-
conserved within the bHLH and bHLH-ZIP proteins, we have not
included them with the other residues in the hydrophobic core.
The functional importance of the residues in the core region
has been shown in a number of mutagenesis studies with the
myogenic and E-proteins (which include El 2 and E47). In myogenin,
the Val 125 residue was changed to an Ala, which resulted in a
reduction in heterodimerization with El 2 or E47 (Winter et al.,
1992). The Phe residue at position 29 is highly conserved
throughout all bHLH and bHLH-ZIP proteins, and where it is not
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conserved, it is replaced with the hydrophobic amino acids Ile, Leu,
or Tyr. Mutagenesis studies of E47 and myogenin have demonstrated
that this Phe residue, along with the residues corresponding to Leu
132, Ile 149, Leu 1 50, Ile 57, and Leu 160, are absolutely essential
for dimerization (Voronova and Baltimore, 990; Winter et al.,
1992).
Reaion A
The region sits at an interface between helix and the
apposing helix 2 (Figure 2b) and includes some residues which are
not within the hydrophobic core (Figure 1 b). There are a number of
charged and polar residues within region A, or close to it, and it has
been proposed that these residues may form salt bridge or hydrogen
bond interactions which may stabilize or destabilize the dimer
interface (Shirakata et al., 993). In the structure of the Myol),
homodimer bound to DNA, we do not see any strong charge-charge or
hydrogen bond interactions in region A. The residues which are
closest to the interface between helix I and helix 2 and which we
have grouped together as belonging to region A are shown in Figures
1 b and 4a. Val 2 in helix is a hydrophobic core residue that
packs against Val 147' of helix 2 and thus, helps to stabilize the
region A interface. The guanidinium group of Arg 151', from helix
21, sits above Val 125 and Val 147', and may help to seclude the
Val-Val interaction from external solvent (the conformation of Arg
151' may be partially stabilized by an intra-helical salt bridge
formed between Arg 151' and Glu 148'). Ala 128, Thr 131, and Ser
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135 (which was mutated from the original cysteine because of
concerns about oxidation; see Chapters 2 and 4 from helix 1, pack
respectively against residues Leu 1 50', Ile 54', and Ile 57' from
the hydrophobic core.
Reaion B
Many parts of the four-helix bundle structure come together
in this region (Figures 1 c and 2c). Analysis of the MyoD hornodimer
structure shows that a key role is played by the tyrosine residue at
position 156 in helix 2 This residue is involved in two important
interactions (Figure 4b). First, it sits above the carboxy terminus
of helix 1, over Thr 36, preventing further extension of helix at
the carboxy terminus, and also stabilizing the amino terminus of
the loop. Second, the OH of Tyr 56 makes a hydrogen bond with the
OE2 of Gin 161' from helix 2 helping to stabilize the dimer
interface in region B. The Tyr residue at position 56 is well-
conserved over the bHLH and bHLH-ZIP proteins (Figure 1 c); the E-
proteins are unique in having a Val residue instead of Tyr residue at
the position equivalent to 56 in MyoD (the structural significance
of the Val residue will be discussed in more detail later).
Mutagenesis results support the importance of Tyr 56 in
stabilizing the MyoD hornodirner structure. A myogenin mutant
where Tyr was substituted by Val, had a reduced ability to
oligomerize and bind DNA (Winter et al., 1992).
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The other residues in region help to stabilize the loop and
the carboxy terminus of helix Lys 3 projects into the interior
of the loop and makes a contact with the carbonyl of residue 142
from the loop; the conformation of Lys 3 3 is also stabilized by a
intrahelical salt bridge between Lys 133 and Gu 130 of helix 1. Thr
136 and Ser 137 at the C-terminus of helix pack against helix 2.
Thr 136 packs against Ala 153 from the hydrophobic core, while Ser
137 points toward Asn 152. The Asn 52 residue is within range to
make a hydrogen bond with Ser 137 of helix 1, but does not do so in
the structure, possibly because it is involved in an intrahelical salt
bridge with Arg 1 5 5.
ReaioLi C
This region comprises three well-conserved residues (Figure
1 d), located near the portion of the hydrophobic core closest to the
DNA, where helix first crosses helix 2 (Figure 2d). The crossing
angle between helices and 2 in MyoD may be partly determined by
the interactions between the residues in this region. Asn 26 is at
the amino terminus of helix 1, near the junction with the basic
region, while Lys 46, the first residue in helix 2 is at the junction
with the loop region. The NZ of Lys 146 contacts the phosphate of
A6, while the main chain amide contacts the phosphate at C5
(Figure 4c). The A6 phosphate is also contacted by ND2 of Asn 126.
Besides the phosphate contact, the OD 1 of Asn 26 makes a
hydrogen bond with the NZ of Lys 146. Thus, the two residues Asn
126 and Lys 146 help 'anchor' the four-helix bundle to the DNA,
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while also stabilizing the conformation of the bundle itself. Phe
129 from helix helps to keep Lys 146 in place as it sits over the
carbon atoms of the Lys side chain. Phe 129 contains an aromatic
ring with an extensive surface for Van der Waals interactions, both
within the core, and with the Lys 146 residue. The structural
importance of the Lys residue at position 146 in MyoD is supported
by mutagenesis experiments with E47 and myogenin. In E47 a Lys
to Ala substitution knocks out oligornerization and DNA binding
(Voronova and Baltimore, 1990), while in myogenin a Lys to Met
substitution reduces oigornerization and DNA binding (Winter et al.,
1992). The Lys residue at position 146 is highly conserved over all
bHLH and bHLH-ZIP proteins (where a Lys residue is not present,
there is an Arg, as in Max). Moreover, the X-ray structures of the
Max (Ferrd-D'Amar6 et al., 1993), USF (Ferrd-D'Amar6 et al., 1994)
and E47 (Ellenberger et al., 1994) complexes all show the Lys (or
Arg in Max) residue in a similar conformation to that seen in MyoD.
S. Heterodimer formation
Several lines of evidence suggest that a heterodimer formed
between MyoD and a member of the E2 proteins (El 2 and E47) is the
biologically active species. First, it appears that in vitro, MyoD
forms heterodimers more efficiently than it forms homodimers (Sun
and Baltimore, 991). Second, examination of whole cell extracts
with antibodies specific for MyoD and the E2 proteins reveals that
MyoD can associate with El 2/E47 in vivo (Lassar et al., 991
Third expression of antisense E2 RNA lowers the level of gene
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expression induced by MyoD (Lassar et al., 991 ). In addition to its
interactions with E47 and El 2 MyoD can also form heterodimers
with the Id protein. Since Id does not have a functional basic
region, formation of the MyoD-Id heterodimer may be a means by
which the DNA binding activity of MyoD is negatively regulated in
trans (Benezra et al., 990). The formation of heterodimers
between Myol) and other bHLH proteins thus appears to be an
important mechanism where the activity of MyoD may be regulated.
In this regard, we note that selection experiments which optimize
the DNA binding site for MyoD and E47 homodimers, and for MyoD-
E47 heterodimers have shown that the three forms of dimer show
subtle difference in DNA binding site preference (Blackwell and
Weintraub, 1990).
We do not yet have a structure of Myol) as part of a
heterodimer, but we are fortunate in having the two homodimer
structures of the MyoD and E47 bHLH domains bound to DNA. A
superposition of the alpha carbon atoms from the two homodimer
structures shows that outside of the loop region, the two
structures are very similar O 0 A rms difference between the alpha
carbon atoms). The high degree of similarity between the bHLH
domains of MyoD and E47 suggested to us that a combination of the
coordinates from the MyoD and E47 homodimer structures would be
a good starting model for the structure of the MyoD-E47
heterodimer. With the assistance of Tom Ellenberger, who kindly
provided us with the E47 homodimer coordinates, we have
constructed such a heterodimer model by a simple substitution of
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the coordinates from one E47 bHLH monomer for the coordinates of
a MyoD bHLH monomer, after the E47 and MyoD homodimer
coordinates were superimposed. The resulting MyoD-E47
heterodimer model shows the familiar four-helix bundle structure
(Figure 5). We note that there are no obvious steric clashes
between residues in this MyoD/E47 heterodimer model. Thus, we
believe that the model is a reasonable approximation for a
functional heterodimer.
In the heterodimer model, the E47 half of the heterodimer has
an extended helix 1, which is one turn longer than helix of Myol)
(Ellenberger et al., 1994). Thus, the substitution of an E47 monomer
for a Mol) monomer in the heterodimer model may create additional
buried surface area for the dimer interface compared to that of the
Myol) homodimer. Aside from this increase in the surface area of
the dimer interface due to the extended helix of the E47 monomer,
there may be other contributions to heterodimer stability which are
significantly more subtle. The core regions of the Myol) homodimer,
the E47 homodimer, and our model of the MyoD-E47 heterodimer are
very similar, with only two out of nine residues in the core being
different between Myol) and E47 (Figure a). It is in region A that
the differences between the Myol) homodimer, the E47 homodimer,
and the MyoD-E47 heterodimer model become more pronounced
(Figure 1 b). In our model of the heterodimer, there are two distinct
region A interfaces: one which has helix from MyoD and helix 2'
from E47, and another which has the reverse arrangement of
helices. At the region A interface with helix from Myol) and helix
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2' from E47, there are several possible interactions between side
chains which could affect the stability of the heterodimer (Figure
6a): 1) In the model, Val 125 from MoD helix packs against Leu
147' from E47 helix 2 (for ease of comparison, the number scheme
follows that used to describe the Myol) homodimer). This Val-Leu
interaction has a greater potential for Van der Waals interactions
than the Val-Val interaction seen in the MyoD homodimer does, and
could be an important factor in heterodimer stabilization (for
comparison, the E47 homodirner has a Ie-Leu interaction at this
part of the region A interface). 2 The Lys 24 from MyoD helix 
has the potential to form a hydrogen bond with Gin 51' from E47
helix 2 (We note that the formation of hydrogen bonds and/or salt
bridges between different subunits has been hypothesized to play an
important role in determining dimer stability and specificity in
UIP proteins (Schuermann et al., 991; O'Shea et al., 1992; Hu et
al., 1993; Vinson et al., 1993). Initial mutagenesis studies with the
bHLH proteins MyoD and E47 also suggest that salt bridges and
hydrogen bonds are important for the dimerization properties of
bHLH proteins (Shirakata et al., 1993).] We note that neither the
MyoD hornodirner nor the E47 homodimer have residues in positions
124 and 151' which could form as good a hydrogen bond pair as Lys
124 and Gin 151'. The Myol) homodimer has a Lys and an Arg at
these positions, respectively, which do not interact in the
structure, possibly because of electrostatic repulsion between the
two residues. The E47 hornodimer has an Asp and a Gin at the
corresponding residues, which are too far apart to form a good
hydrogen bond pair (Ellenberger et al., 1994) 3 At the carboxy
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terminus of this region A interface, the residues Ser 135 from MyoD
helix 1 and Leu 1 58' from E47 helix 2 could interact. It is difficult
to predict a priori the energetics of such a potential interaction,
especially in comparison to the energetics of the interactions
between Ser 35 and Glu 158' from the Myol) homodimer structure,
and between Met 135 and Leu 158' from the E47 homodirner
structure.
At the other region A interface formed between helix of E47
and helix 2 of Myol), there are also a number of interesting
interactions which are possible (Figure 6b): 1) In the model, Ile 125
from E47 helix packs against Val 147' from Myol) helix 2 and as
with the Val-Leu pair at the other region A interface of the
heterodimer, the Ile-Val pair here would likely have a more
favorable energy of interaction than the Val-Val pair found in the
Myol) hornodirner structure. 2 Asp 124 from E47 helix I could form
a salt bridge with Arg 51' from MyoD helix 2 3 In lieu of a
potential salt bridge with Asp 124, the Arg 51' residue could form
a salt bridge with Glu 31 of E47 helix 1. We cannot predict a
priori whether the Asp 124 - Arg 51' interaction would contribute
more to the heterodimer stability than the Glu 31 - Arg 1511
interaction would. We do note, though, that neither the MyoD
homodirner nor the E47 homodirner structures have residues which
could form a stable salt bridge or hydrogen bond between residues
at positions 131 and 1 51' 4 At the carboxy terminus of this
region A interface, the Met 135 from the E47 helix and the Glu
158' from the Myol) helix 2' could interact. As with Ser 135 and Leu
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158' from the other region A interface, however, we cannot easily
predict the energetics of the potential Met 135 - Glu 1 58.'
interaction.
Outside of region A, the potential interactions at the dimer
interface of the heterodimer model do not differ so much from the
interactions seen at the dimer interfaces of the Myol) and E47
homodimer structures. In region C, for example, the interactions
between Asn 126 from helix 1, Phe 129 from helix 1, and Lys 146
from helix 2 are nearly identical in the Myol) and E47 homodimer
structures, and as a result, are predicted to be very similar in the
MyoD-E47 heterodimer model. For region B, the individual dimer
interfaces for each half of the heterodimer look similar to the
corresponding homodimer interfaces. Thus, in the heterodimer
model, the region interface formed by the Myol) helix 1, loop, and
helix 2 and the E47 helix 2 (Figure 6c) looks similar to the same
region in the Myol) homodimer (Figure 4b). At the other region 
interface for the heterodimer, formed by the E47 helix 1, loop, and
helix 2 and the MyoD helix 2 the configuration of the amino acids
(Figure 6d) is nearly identical to that seen in the E47 homodimer
structure (Figure in Ellenberger et al., 1994). Thus, the carboxy
terminus of helix is extended by one more turn than is seen in the
Myol) and Max hornodimer structures because replacing the Tyr
residue at position 158 with a smaller Val residue removes ihe
steric constraint on the extension of helix (compare Figure d
with Figure 4b).
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In summary, the MyoD-E47 heterodimer model predicts that
the major determinants for the greater stability of the heterodimer
vis-a-vis the MyoD homodimer are to be found in two regions of the
dimer interface. First, in region B, the extended helix in the E47
monomer provides additional buried surface area at the dimer
interface without losing any potential hydrogen bonds: the Tyr 56 -
Gin 161' hydrogen bond interaction seen in the MyoD homodimer
structure (Figure 4b) is replaced by a His 139 - Gln 61' hydrogen
bond interaction in the MyoD-E47 heterodimer model (Figure 6d).
Second, in region A, the potential hydrogen bonds and/or salt
bridges which can form in the MyoD-E47 heterodimer, but not in the
MyoD or E47 homodimers, will be expected to stabilize the
heterodimer interface. A number of recent mutagenesis studies
involving the Id, MyoD, El 2 and E47 proteins provide some support
for our model of dirner stabilization. The importance of residues in
region for dimer stability is supported by recent studies on the Id
protein (Pesce and Benezra, 1993). The Id protein is unique among
bHLH proteins in that it does not form hornodimers with itself, but
does form heterodimers with MyoD and E47 (Benezra et al., 990;
Jen et al., 992; Sun.et al., 991 ). Replacing four residues in the
helix /loop junction in region of El 2 or E47 MHL) with the
corresponding residues from Id (PTLP) conferred the Id dimerization
specificity on the E-proteins, that is, the mutant E-proteins were
unable to form homodimers, but could form heterodimers with MyoD
(Pesce and Benezra, 1993). As discussed in the report on the E47
homodimer structure, the Id residues introduced in region could
significantly alter the structure of this region and thus, interfere
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with E47 homodirner formation (Ellenberger et al., 994). As for
region A, a recent mutagenesis study on MyoD showed that
substituting the region A residues Thr 131 and Cys 35 from helix 
with lie and Arg, respectively, could significantly decrease the
ability of the mutant to form heterodimers with El 2 (Shirakata et
al., 1993). More mutagenesis studies need to be done in order to
fully address the role played by residues in regions A and B, but the
data, thus far, supports the importance of these residues in
influencing homodimer and heterodimer stability.
C. Dimerization in the bHLH family of proteins
For MyoD and E47, differences in regions A and of the dirner
interface may contribute to dimer specificity. In region C, the
residues are identical in MyoD and E47, but there are other bHLH
proteins which have significant differences in this region. These
differences in sequence, especially at position 129 where a Phe
residue is usually found, might have significant effects on the
ofigomerization properties of the bHLH proteins. The structure of
the USF bHLH domain bound to DNA (in which the normally present
zipper was deleted for crystallization purposes) has recently been
solved (Ferr6-D'Amar6 et al., 1994). The USF bHLH domain shows a
fold that is similar, but not identical, to the parallel four-helix
bundle structure seen in Max, E47, and Myo!). In particular, the USF
bHLH fold shows a significantly different crossing angle between
helices and 2 at the part of the hydrophobic core closest to the
DNA. This difference in crossing angle causes the USF bHLH
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structure to have helices 2 and 2 splayed away from the dimer axis,
in comparison to Max, E47 and MyoD. The USF protein normally has a
leucine zipper extension, as does Max, and indeed, the bHLH domain
by itself (in contrast to the full bHLH-ZIP domain) dimerizes poorly
and binds DNA poorly (Ferrd-D'Arnar6 et al., 1994). Although, it may
thus be difficult to draw any firm conclusions about dirrierization
based on the USF bHLH structure, it is nonetheless interesting to
note that the difference in helix crossing angle between USF and the
other three bHLH(/Z) structures may be linked to a difference in
structure in region C. Instead of a Phe residue at position 29,
which is found in Max, MyoD, and E47, USF has a Ile residue (Figure
1 d). In the Myol) structure, the Phe 29 residue packs tightly
against Ile 149 and Leu 150, as well as against residues from the
other dimeric partner, Phe 29', Ile 149' and Leu 150' (Figure 7.
Substituting a Ile residue for the Phe might be expected to
significantly affect the amount of surface area available for Van
der Waals interactions within the hydrophobic core, if the
orientation of the helices within the core were unchanged. If the
helices adopted different crossing angles, however, the residue
change from Phe to Ile might be better accommodated. A recent
mutagenesis study, which tested the importance of the sequence
identity of residue 129 in MyoD, finds that substituting Phe with
Ala, Val, Ile, Leu, or Trp significantly reduces the protein's
dimerization potential (Shirakata et al., 1 993). One mutation, a Tyr
substitution, retained more of the original dimerization potential,
presumably because Tyr is quite close in structure to Phe.
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Aside from the different hydrophobic residues which can be
found at position 129, the differences in residue identity within the
hydrophobic core are quite subtle, and a comparison of the
structures of Max, USF, E47, and MyoD does not suggest any obvious
way in which this residue variability may affect the structure of
the four-helix bundle. More structures of bHLH and bHLH-ZIP
proteins with different sequences in the core region will need to be
solved before we can more fully address this question. In this
regard, we note that it is still not clear how important the
sequence identity in hydrophobic core regions is for determining the
structure of proteins in general. Earlier studies have shown that
the pattern of hydrophobic and polar residues, rather than the actual
sequence identity for each residue, is the more important factor in
determining protein structure (Lim and Sauer, 991; Dao-pin et a.,
1991; Bowie et al., 1992). More recently, a detailed study on GCN4
zipper mutants has shown that the sequence identity of the residues
at the a and d positions of a coiled coil (which can be thought of as
constituting the hydrophobic core for this type of structure), has a
key role to play in determining whether the alpha-helices of the
GCN4 mutants form two-, three-, or four-helical bundles (Harbury
et al., 1993). Given that all of the bHLH and bHLH-ZIP structures
solved thus far show a parallel, four-helix bundle conformation, it
will be interesting to see if mutations in the core region will
significantly affect the packing arrangements of the helices.
We note that all of our analysis has been based upon the
structures of bHLH and bHLH-ZIP proteins bound to DNA as
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hornodirners. In the absence of DNA, various studies have shown
that bHLH-ZlP and bHLH proteins can interact as tetrarners as well
as dimers (Dang et al., 1989; Hu et al., 1990; Fisher et al., 1991;
Anthony-Cahill et al., 1992; Starovasnik et al., 1992; Farmer et al.,
1992). Recent studies with the USF protein also suggest that under
certain conditions, the protein may associate with DNA as a
hornotetrarner (Ferr6-D'Arnar6 et al., 1994). For the myogenic and
E-proteins, at least, the evidence suggests that the proteins bind to
DNA as dirners, even though they may associate in different
oligorneric forms in the absence of DNA (Farmer et al., 1992; Lassar
et al., 1991; Fairman et al., 1993). Thus, for the purpose of
understanding the structural basis for the bHLH proteins'
involvement in gene regulation, we feel justified in focusing our
discussion on dirnerization. As we discuss in the next section, a
detailed understanding of dirnerization preferences and the role of
dirnerization in regulating biological activity will require the
solution of heterodirner structures, as well as careful study of
dimer stabilities and DNA binding constants. We also note that our
structural analysis has focused on the bHLH regions of these
proteins. Other regions of the proteins may influence the
dirnerization states. Further mutational and deletional analysis of
the bHLH(-ZIP) proteins may help to address this possibility.
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Figure 1: Amino acid identities of residues at the dimer
interface for bHLH and bHLH-ZIP proteins.
Sequence alignment of the helix-loop-helix region of members of
the bHLH (above dashed line) and bHLH-ZIP families (below dashed
line). Key residue positions were identified by looking for
conserved residues within the primary sequences and/or by using
the structure of the MyoD/DNA complex as a template. Figure a
highlights the residues within the hydrophobic core. The
hydrophobic core residues are shown in stippled boxes. Figure b
also shows the hydrophobic core residues within stippled boxes. In
addition, it shows residues at the dirner interface corresponding to
region A (between helix and helix 2. These residues from region
A are underlined and highlighted in bold. Figure I c shows the
hydrophobic core residues and residues from the dimer interface
corresponding to region (where the carboxy terminus of helix ,
the loop, and parts of helices 2 and 2 meet). These residues are
underlined and highlighted in bold. For E47, the residues from the
homodimer structure (Ellenberger et al., 994) which were
identified as being important for dimerization are italicized,
underlined, and highlighted in bold. Figure 1 d shows the hydrophobic
core residues and the residues from region C of the dimer interface
(where helix first crosses helix 2. As in Figures I b and 1 c, the
key residues are highlighted in bold and underlined.
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Figure 2 Overview of the Myol) helix-loop-helix
dimerization motif, highlighting residues at the dimer
interface.
We show the alpha carbon trace of the helix-loop-helix regions of
MyoD in blue. Key residues which are important for dimerization
stability and/or specificity are shown in red. Figure 2a shows the
position of residues within the hydrophobic core in red. Figure b
shows the positions and side chain residues from region A in red.
Figure 2c shows the positions and side chain residues from region 
in red. Figure 2d shows the positions and side chain residues from
region C in red.
Figure 3 A tetrad of leucines at the carboxy termini of a
Myol) dimer help to stabilize the dimer interface.
The alpha carbon traces of helices 2 and 2 are shown in red. The
side chains of leucine residues 163 and 164, and the symmetry
related residues (Leu 63' and Leu 64') are represented by ball-
and-stick models in blue.
Figure 4 Key residues at the dimer interface of the Myol)
homodimer.
Ball-and-stick models of important residues at each of the three
key regions of the dimer interface. Figure 4a shows residues from
region A. We have labeled important residues that are involved or
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may be involved in dimerization stability and/or specification for
the MyoD homodimer: from helix 1, these are Lys 124, Val 125, Ala
128, Thr 131, and Ser 135 (we had replaced the normally present
cysteine at this position with serine because of concerns about
oxidation during the cocrystallization experiments); from helix 2'
(from the symmetry-related monomer), these residues are Val 147',
Arg 1 51 , and Gu 1 58'. Figure 4b shows residues from region B. We
show the following key residues: from the carboxy terminal end of
helix 1, Lys 33, Thr 136, and Ser 137; from helix 2 Asn 52 and
Tyr 156; and from helix 2 Gin 61'. Figure 4c shows residues from
region C, where helices and 2 cross each other for the first time,
and where the four helix bundle is 'anchored' to the DNA phosphate
backbone. The important residues shown are Asn 126 and Phe 29
from helix 1, and Lys 146 from helix 2 The nucleotides from C5 and
A6 are also shown. Figures made with PREMA (M. Rould).
Figure 5: Model of the MyoD-E47 heterodimer.
We used the ISQ command from the graphics program 0 (Jones et
al., 1991) to superimpose the coordinates of the E47 homodimer
(provided by T. Ellenberger and S.C. Harrison, Harvard University) on
the MyoD homodimer coordinates. The MyoD-E47 heterodimer model
consists of one monomer from the MyoD dimer combined with one
monomer from the superimposed E47 dimer. The heterodimer model
is shown 'bound' to the DNA site from the MyoD homodimer
structure. Residues from MyoD are shown in magenta, those from
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E47 are shown in red. Notice that the carboxy terminus of helix is
extended in the E47 monomer compared to that of MyoD.
Figure 6 Key residues from the dimer interface of the
MyoD-E47 heterodimer model.
We show residues from the heterodimer model which correspond to
the regions and 2 shown in Figure 4 For purposes of exposition,
we use the MyolD numbering scheme for residues. Thus, the E47
residues are numbered according to the scheme used for MyoD.
Figure 6a shows the region A interface where helix is from MyoD
and helix 2 is from E47. We show side chains from key residues
that may be important for heterodimer stabilization and/or
specificity: from Myol), Lys 124, Val 125, Ala 128, Thr 131, and Ser
135; from E47, Leu (1 47% Gin (I 51% and Leu (1 58'). Figure b
shows region A where helix is from E47 and helix 2 from MyoD.
The key residues are: from E47, Asp (1 24), lie (1 25), Ala (1 28), Glu
(11 3 1 ), and Met ( 3 ); from MyoD, Val 471, Arg 1 5 1', and Glu 1 5 8'.
Figure 6c shows the region interface where the carboxy terminal
end of helix and residues from helix 2 of Myol) meet helix 2 from
E47. The important residues are similar to those shown in Figure
4b for the MyoD homodimer, except that a Glu residue from E47
replaces that of a Gn from Myol) at position 161'. Figure 6d shows
region from the other half of the heterodimer. Here, the tarboxy
terminus of helix 1, along with parts of loop region and helix 2 from
E47 meet helix 2 from Myol). We show E47 residues which were
identified from the E47 homodimer structure to be important for
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dirner stabilization (Ellenberger et al., 1994) Gn (I 37), His (1 39),
Leu (1 40) Gn (1 44), Gin (1 52) and Val (1 56). Notice that the
carboxy terminus of helix from E47 is extended by an additional
turn compared to that of helix from MyoD. In the E47 homodirner
structure, a Glu at position 161' from helix 2 makes a hydrogen
bond contact with the His at position 139. Here, in the heterodimer
model, helix 2 is from Myol), and a Gin replaces the E47 Glu at
position 161'. Figures made with PREMA (M. Rould)
Figure 7 The interior of the core around the residues of
region C.
We show a view looking down the dirner axis of the four-helix
bundle from the Myol) homodimer. Hence we look down from the
carboxy termini towards the amino termini of helices and 1' and
helices 2 and 2 We show key residues involved in dimer
stabilization at the region where helix first crosses helix 2 from
helices and 1', Phe 129 and 129'; from helices 2 and 2 Ile 149,
Leu 1 50, Ile 149', and Leu 150'. Figure made with PREMA (M. Rould).
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helix loop helix 2
46ALMyoD l.-,.V-"".'NEA-""..-..ETEKRCTS ---- SNP ----------- NQRLPKVEfbRNA1RY----
M,fiGRMCQ ---- MHLK ---------E47 QQ
Twist SLNDAF-..-.-KS IIP ---- TLP ----------- SDKL S KI QT§..."iKIM RM
Kii
AS-C sc QWNSRM-L-"".-RQHIPQSIITDLTKG--G-GRGPHKKISKVDTi;.kIifty DL
ilxi
AS1Id Di&GCji MikELVP ---- TLP ---------- QNRKVSKVE---. vby LE
10.
Tall NW G &J-AE -L-RK LI P ---- THPP ---------- DKKLSKNE-jLRLAMKY
gii; M
Hairy RF4NcL--'-NEV---'-.-KT L I L ---- DATKKDPA-----RHSKLEKADI KT. H RQ
--------------------------------------
N-Myc DDk S S E LT.L-------RD HVP --------- EL ----- VKNEKAAKVVi-L..-.XKATEYVH%.-.-.-QAE
C-Myc FLXRSPFAIRDQIP --------- EL ----- ENNEKAPKVV-j-i---L----'.- A shiftAE
Rising
Max I -, M- S H S M S V P --------- SLQG ------ QKASRA E Y
K::
M` ig::
USF Cj SKIIP----DC-SMEST ------ KSGQSKGG:;:::::::::
S D QS
MW
VD TLIP------ KSSDP ------- QmRwNK STFE3 Y--'-XR KE
R
'A E
AP4 S1--NAGf QS LIP ------- HTD -------- -F QE
PH04 RPAVA4--'-"HE SLIP --------- EWKQ--QNVSAMSKA ETT--V-- H QN
Figure I a
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helix loop helix 2
EE ;!R ALEaft L UkQTS----SNP----------- NQRLPnMyoD
E47 GRMQQ ---- MHLK --------- SDKAQTQL
Twist P----TLP ----------- SDKLS
AS-C SC Q PQSIITDLTKG--G-GRGPHKKISIWT QDL
---- TLP ---------- QNRKVSIW QLEId G
PJLIP ---- THPP ---------- DKKLSIW AKLTall
Hairy L ---- DATKKDPA-----RHSKLE QRQ
--------------------------------------
KAAKZv....lN-Myc --------- EL ----- VKNE
C-Myc --------- EL ----- ENNE KAP
--------- SLQG ------Max
USF KZIP---- DC-SMEST------ KSGQS CD RQSffi
QKETFE3 P------ KSSDP ------- QMRWNY12TF
AP4 IP ------- HTD -------- GEKLSKAAWQ QE
PH04 'Lip --------- EWKQ--QNVSAAPSK,&T R QQN
Figure 1 b
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helix loop helix 2
;pFVWXj'EGL.QALMyoD KVNE -- SNP ----------- NQRLPKVE.-.l
*Rii SDKAQTKLE47 E J ---------1A.-P
S: WfDAZXS'.l, QI, KLSKIQ
Twist M ---- TLP ----------- SD
VQW 4NS.--F: Z.----.j&QHjX G--G-GRGPHKKISKVD LAS-C sc F  QSIITDLTK
Id DWG(*SRWLM----TLP ---------- QNRKVSKVE1
Tall 19W-.GA M.-MMIZZ ---- THPP ---------- DKKLSKNE2------
Hairy f&NCUEqgLM ---- DATKKDPA ----- RHSKLEa
---------------- ---------------------
KAAKVV1-LN-Myc DIaSSELTIL DKM --------- EL-----VKNE KKATE LQAE
C-Myc --------- EL ----- ENNEKAPKVV-;,--A1qV.7A3
"'R
Max SVHSMPS3M --------- SLQG ------ QKASRAQ..- ,F KLIZWEX QY.'.ZP
gg
---- DC-SMEST DI
------ KS GQ SKGUSF
TFE3 D KE& LIZ------KSSDP ------- QMRWNKGT-j---VYAS
INE
AP4 AG QSMTL;a ------- HTD -------- GEKLSKAASQ!QT
PH04 SIZE --------- EWKQ--QNVSAAP TSKA
Figure 1 c
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helix loop helix 2
MyoD AV T:k*:: ---- SNP ----------- NQRLP Y
UWE JZRCTS 4,QAL
..... ... .
E47 Q-$.'GRMC --- MHLK --------- SDKAQT]SLLXIWQ V 4--G QQ
Twist S, SiOQIIP----TLP ----------- SDKLSEIQT L Y
IR
AS-C sc S lioRQHIPQSIITDLTKG--G-GRGPHKKISKMT I Y S
Id LVP ---- TLP ---------- QNRKVSKVE H Yt--RD LE
Tall IP----THPP ---------- DKKLS E L Y NF
Hairy E LIL ---- DATKKDPA ----- RHSKLEEAD K H Efp .
--------------------------------------
N-Myc SSj:M'W'!: -L-"-KKATE Sam
HVP --------- EL-----VKNEKAAZWI--.
Militia:
C-Myc EL --------- EL-----ENNEKAP KNTAY SvQAE
QJP KWP-P
Max HjXD
YW.-RK
.HSOMSVP --------- SLQG ------ QKASI&A K
7;
USF giMMIva.....-ISKI IP ---- DC-SMEST ------ KSGQSEGG, D QS
Fiji!!
TFE3 !j::: TLIP ------ KSSDP ------- QMRPRMGT S Y14 77.
AP4 S, GXQS..L-.'Y-,TLIP ------- HTD -------- GEKLSKAA QT Y. S QEOv
g
PH04 RL&VA&HEf.---'SLIP --------- EWKQ--QNVSAApS]SAT RY H.
Figure d
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CHAPTER 6
The Structural Basis for the Control of
Gene Regulation by MyoD:
Outlook for Future Experiments
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At this stage, we can answer many of the structural and
biological questions that motivated this work. In summary, we
have: 1 Determined that the fold of the MyoD bHLH domain is very
similar to that of the Max bHLH domain, and the E47 bHLH domain,
but is less similar to the USF bHLH domain (which may be a result
of the deletion of the leucine zipper from the normal bHLH/Z domain
of USF). It thus appears that the bHLH domain is a fairly well-
conserved fold. 2 Determined the basis of specificity for the
conserved four bases in the central E-box DNA binding site
(.CANNIQ), as well as for a few of the flanking base pairs. 3 Shown
that a conserved core of hydrophobic residues within the four helix
bundle forms the bulk of the dimer interface for the Myol) homo-
dimer. We have also identified a few regions of the dimer interface
which contain residues that may be important in influencing homo-
dimer and heterodimer stability. 4 Examined the positions of the
postive control mutants in the context of the MyoD structure. Two
of these residues, Ala 1 4 and Thr I 5, are found to be buried
within the major groove of the DNA, and hence, are not likely to
interact directly with other proteins. We have found, though, that
Ala I 4 and Thr 1 1 5 may determine the structure of Arg 1 1 1, and
we hypothesize that the position of Arg 1 1 1 could have an effect on
the transcriptional activity of MyoD.
Even as we have met some of our initial goals in our study of
Myol), there are questions about the structure and function of the
MyoD bHLH domain that remain to be answered. Indeed, a number of
these questions have arisen only after the determination of the
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crystal structure. In the following section, we outline a few of
these outstanding questions and suggest possible directions for
future research.
A. Tertiary fold
The four crystal structures of bHLH and bHLH/Z proteins which
have been solved recently show that the parallel four-helix bundle
fold is very well conserved. In particular, three of the four struc-
tures, those of Max, E47, and Myol), have very similar structures in
the four-helix bundle region (Figure 1). [Conver-sations with Adrian
Ferr6-1)'Amar6 and Stephen Burley support our observation that the
structure of the USF bHLH region is significantly different from
that of Max and MyoD.] From sequence comparisons of the four
proteins (Max, USF, E47 and Mol)), it appears that the hydrophobic
core accounts for much of the conservation of structure in the
four-helix bundle fold. It would be interesting to learn how residue
changes within the hydrophobic core change the structure of the
four-helix bundle. As discussed in the previous chapter, there is
still some uncertainty about how the identity of hydrophobic
residues affects the structure of proteins, in general. Mutagenesis
experiments on the hydrophobic core region of Myol) may help
determine how the structure of the four-helix bundle is affected by
different hydrophobic residues, and may also add to our
understanding of the importance of hydrophobic residues for protein
structures, in general. One could make random changes in the core
region of Myol) by means of cassette mutagenesis (Reidhaar-Olson
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et al., 1991), screen the mutants for DNA binding activity and
oligomerization potential, and then determine the structures of the
most interesting mutants. Alternatively, one could use a more
directed approach to mutagenesis, such as that used in one study on
Myol) (Shirakata et al., 1993), and make systematic residue changes
at one or more of the positions in the core.
B. DNA recognition
There is one important question about DNA recognition by
Myol) that was not fully answered by the structure of the MyoD-DNA
complex, and that question has to do with the specificity for the
central base pairs of the Myol) binding site. Myol), along with most
other bHLH proteins, has a DNA binding preference for CAMTG, and
against ACQTG (Blackwell and Weintraub, 1990). In contrast, Max,
myc, and most other bHLH/Z proteins seem to preferentially bind
CACQTG over CAC&TG (Dang et al., 1992; Blackwell et al., 1993).
The structure of the Max complex showed that an Arg, at a position
corresponding to Leu 122 in Myol), made a hydrogen bond contact to
the N7 atom of the central G base in CAC.QTG Verr6-1)'Amar6 et al.,
1993). A similar arginine-guanine contact was seen in the struc-
ture of the USF complex (Ferr6-D'Amar6 et al., 1994). In contrast to
this defined arginine-guanine contact in the Max and USF structures,
the structure of the Myol) complex did not show any direct contacts
at the central base pairs. Indeed, the leucine residue at position
122 was not in a good position to make any sort of base-specific
contact at the central base pairs. [The structure of the E47 complex
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showed that the Val residue at position 22 does not make any
contact to the central base pairs either (Ellen-berger et aL, 994)].
It appears, then, that the bHLH proteins may have different
mechanisms for recognizing the central base pairs than do the
bHLH/Z proteins. The mechanisms used by the bHLH proteins may
depend upon the sequence being recognized. Selection experiments
had revealed that while the MyoD hornodimer prefers the symmetric
DNA sequence CAGCTG, the E47 hornodimer or the MyoD-E47
heterodimer prefers the asymmetric DNA sequence CAGGTG
(Blackwell et aL, 990). In the E47 structure, where the protein is
bound to DNA containing the sequence CAGGTG, one of the basic
regions has an Arg (corresponding to Arg I 9 in MyoD) that makes a
contact to the N7 of the central G base in CAG.QTG (Ellen-berger et
al., 1994). The other basic region has the Arg residue making a
phosphate contact (both of the Arg 1 9 residues in the Myol)
homodirner make phosphate contacts). In the MyoD homodimer
structure, which contains the sequence CAGCTG, there are no direct
contacts made to the central base pairs, although there is a water-
mediated contact made by Glu I to the central C base in CAG.QTG.
Given the resolution limit of 28 A in the MyoD structure, however,
one cannot make a definitive conclusion about the importance of
water-mediated contacts.
We have seen, then, that for the MyoD hornodimer, the basis of
specificity for the central bases in CAC&TG does not appear to be
due to direct base contacts, but may rather be due to water-
mediated contacts and/or an indirect readout mechanism that
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senses sequence-dependent changes in the phosphate backbone. in
order to clarify this question of specificity for the central base
pairs, we can take several approaches. The first is to obtain a
higher resolution structure of the MyoD homodimer bound to DNA
site containing the sequence CAMTG. The MyoD cocrystals which
we used in our structure determination have an effective resolution
limit of 28 A. It might be possible to get better diffraction by
finding new crystallization conditions, possibly using a slightly
different DNA site. Flash-freezing the crystals with liquid nitrogen
after treating the crystals with an appropriate cryoprotectant
(Petsko, 1975), may extend the resolution of diffraction by limiting
radiation damage during data collection. We had earlier exper-
imented with flash-freezing, but since our crystals were very
sensitive to mechanical stress and changes in mother liquor (see
Chapter 3, we were unable to find a cryoprotectant that did not
damage the crystals. At this stage, then, it appears, then, finding
new crystallization conditions may be the best means of getting
better diffracting crystals. Aside from obtaining a higher resol-
ution structure of the Myol) complex, we might get more
information about specificity for the central base pairs by
cocrystallizing Myol) with DNA sequences that differ at the center.
A crystal structure of Myol) bound to a DNA site containing CACQTG
might reveal why this site is not favored by Myol). [Although Myol)
binds poorly to the CAQTG site in gel shift experiments (Blackwell
et al., 1993), the millimolar concentrations of protein and DNA used
in crystallization experiments may be high enough to compensate
for the poor DNA binding.]
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C. Dimerization
Dimerization has been shown to be an important determinant
of the biological activities for the bHLH(-ZIP) and UIP families of
transcriptional regulators (for a review, see Ellenberger, 994) In
Chapter 5, we examined some of the details of the dimer interface
in the Myol) homodimer structure. In particular, we identified three
regions of the dimer interface that may be especially important for
determining the specificity of dimer formation. We also presented
a model of the MyoD-E47 heterodimer, based on the coordinates of
the Myol) homodimer and E47 homodimer (Ellenberger et al., 1994).
Although our model has identified a few residues that may be
important for heterodimer specification, definitive conclusions
about how the MyoD-E47 heterodimer is stabilized will have to
await the solution of a heterodimer structure. The biggest barriers
to obtaining a structure of the heterodimer will likely be at the
purification and crystallization stages. Since a mixture of Myol)
and E47 will result in an equilibrium of Myol) homodimers, E47
homodimers and MyoD-E47 heterodimers (Sun and Baltimore, 1991),
it is likely that there would be significant problems of
microheterogeneities during purification and crystallization. One
way around this problem of homodimer-heterodimer equilibrium,
would be to use a covalently-linked heterodimer. Heterodimers of
Myol) tethered to E47 by cysteine disulfide bonds (Anthony-Cahill et
al., 1992; Fairman et al., 1993), or by flexible polypeptide linkers
(Neuhold and Wold, 1993) have been constructed and shown to bind
DNA effectively. Moreover, once these tethered heterodimers are
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formed, they are difficult to break apart, as they seem to be
resistant to negative inhibition by the Id protein (Fairman et al.,
1993; Neuhold and Wold, 1993). Thus, a tethered heterodirner is
likely to be stably folded and a good candidate for crystallization
studies. We would probably need to generate a number of different
tethered heterodimers, joined by linkers of various length and
composition, before finding one that produced suitable crystals.
Short of solving a crystal structure of a MyoD-E47
heterodimer (tethered or not), we could get some information about
the determinants for heterodimer formation by means of
mutagenesis experiments. In Chapter 5, we identified a few
residues in regions A and of the dirner interface that might be
important for heterodimer stabilization. We could test our theories
by making directed mutations at these residues, and then checking
to see how these mutations affected homodirnerization and
heterodimerization. A recent study on MyoD used such an approach
to generate a Myol) mutant that had an increased preference for
homodimerization (Shirakata et al., 1993; the change was in a
residue in region A: Thr 131 to Glu). By using directed mutagenesis
at other residues at the dimer interface to generate MyoD and E47
mutants that had different preferences for homodirneration and
heterodirnerization, we could learn more about the rules for
heterodimer and hornodimer formation. A detailed study of dirner
formation among the myogenic proteins (wh ich would include
structural studies, careful measurements of dimer stability and
DNA binding affinities of different homo- and heterodimers, as well
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as mutagenesis experiments) may add to our understanding of how
dimerization controls the activities of bHLH and bIP proteins, in
general.
D. Transcriptional Activation
The structure of the MyoD complex revealed that the positive
control mutants may influence transcriptional activation indirectly
through determining the position of Arg 1 1 1 in the basic region. We
can test this hypothesis by generating mutants in the positive
control residues and testing for their ability to bind DNA and
activate transcription. Previous studies showed that a Thr to Asn
substitution at position 1 1 5 generated a mutant that was able to
bind DNA as well as activate transcription (Bengal et al., 9 94).
This result is consistent with our model since in the MyoD
structure, Thr 1 1 5 makes a phosphate and base specific contact. An
Asn substituted for the Thr would still be able to make a contact to
the DNA without significantly affecting the position of Arg 1 1 1 In
contrast to the mutations at position 1 1 5, mutations at Ala 1 4
would be expected to have an effect on the position of Arg 1 1 1.
Thus, an Ala to Asp substitution at position 1 4 resulted in a
mutant that still bound DNA, but was no longer able to activate
transcription (Bengal et al., 994). It will be interesting to test if
other mutations at position 14 can generate the same phenotype as
the Ala to Asp substitution. Such mutagenesis studies are currently
under way (Weintraub et al., personal communication). In addition
to further mutagenesis studies at positions 1 4 and 1 1 5, our
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collaborators are currently attempting to generate second site
reverants to the positive control mutants by changing the identity
of the residue at position 1 1 1 (Weintraub et al., personal
communication). Once these revertants are identified, it would be
quite interesting to determine their structures.
The work presented in this thesis has concentrated on
describing the bHLH region of Myol). There are other areas of the
protein which are important for biological activity. For example,
the first 53 residues of MyoD have been shown to function as a
transcriptional activation region when fused to the GAL4 DNA
binding domain (Weintraub et al., 991 ). It will be very interesting
to see how this N-terminal activation region interacts with other
regions of Myol), especially the bHLH region. A deeper understanding
of how the positive control residues affect transcription may come
from solving the structure of the intact Myol) protein, or else, a
fragment of the protein which contains both the N-terminal
activation and bHLH regions. Proteolytic dissection of the lambda
repressor protein revealed that an amino-terminal domain binds
DNA and that a carboxy-terminal domain mediates oligomerization
(Pabo et al., 1 979). Proteolytic digestion experiments with Myol) in
the presence and absence of DNA, may uncover a protease-resistant
domain of the protein that maintains both DNA binding and
transcriptional activities. If such a stable domain can be found, it
would be a good candidate for further structural studies.
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Figure Legend
Figure 1: Superposition of the basic-helix-loop-helix
regions of Max, E47, and MyoD reveal a strongly conserved
tertiary fold.
We used the program (Jones et al., 1991) to superimpose the
coordinates of the bHLH regions of the Max hornodimer structure
(provided by Stephen Burley, Rockefeller University), and the E47
homodimer structure (provided by Tom Ellenberger and S.C. Harrison,
Harvard University) on the coordinates of the MyoD hornodirner
structure. As first suggested in the report on the Max structure
(Ferr6-D'Arnard et al., 993), the superposition reveals that the
four-helix bundle domain is remarkably well conserved between the
three structures. The three bHLH domains are shown 'bound' to DNA
from the MyoD hornodirner structure. Residues from MyoD are shown
in magenta, those from E47 are in red, and those from Max are in
green.
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IFigure
